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Proteases are enzymes that cleave protein amide bonds.  Proteases are involved in 
a myriad of biological processes and are considered favorable targets for drug design.  
The proteases described herein are cysteine proteases, which utilize a cysteine residue 
thiol to attack the amide carbonyl, leading to amide bond cleavage.  Irreversible 
inhibitors of cysteine proteases react with the active site cysteine, forming a covalent 
bond and rendering the enzyme inactive. 
The first project involved the design and synthesis of aza-peptide epoxide 
inhibitors for calpain, a clan CA, ubiquitous, calcium-activated human enzyme involved 
in neurodegeneration.  These inhibitors proved to be poor inactivators of calpain, 
demonstrating that the aza-peptide epoxide is a warhead specific to clan CD cysteine 
proteases (caspases, gingipains).  Subsequently, a known epoxide inhibitor of calpain was 
optimized to create a more potent inhibitor.  Several of these inhibitors were more potent 
than the parent, and all were demonstrated to inhibit calpain in a breast cancer cell line 
which was treated with paclitaxel to spike calpain activity. 
The second project involved the design and solid phase synthesis of aza-peptide 
Michael acceptor caspases inhibitors.  The two goals of this project were to develop a 
solid phase method for synthesis of inhibitors that are tedious to synthesize in solution 
phase, and to use a variety of amino acid residues to determine the optimal interactions in 
 xxi
the P3’ position for various caspases.  The synthesis was successful, and the optimal P3’ 
residues were determined. 
The third project involved the kinetic evaluation of aza-peptide epoxide and 
Michael acceptor inhibitor designed for the gingipains.  Gingipains K and R are virulence 
factors in the pathology of Porphyromonas gingivalis involved in gingivitis and 
periodontal disease.  These inhibitors proved to be extremely potent inactivators of 
gingipains, with some of the highest rates of inhibition measured in the Powers 
laboratory.  Gingipain K preferred larger, aromatic moieties in the P1’ position, while 
gingipain R preferred the Michael acceptor inhibitors, with the P1’ substituent having 








Proteases.  Proteases are enzymes that hydrolyze amide bonds of peptide substrates.  
These enzymes are present in all living organisms, and comprise more than 2% of the 
human genome.1  Proteases are involved in a large number of biological regulatory 
processes and systems, such as simple food digestion, protein activation, and protein 
synthesis.  Proteases are involved in inflammation, fertilization, allergic reactions, cell 
growth and death, blood clotting, tumor growth, and bone remodeling.  Because of the 
ubiquitous nature of proteases in biological processes, they have been prime targets of 
inhibitor design and have been identified as therapeutic targets for many diseases and 
conditions. 
 
Protease Clans.  Proteases have been divided into classes, clans, and families based on 
their mechanism of action and overall structural fold (Figure 1.1).2,3  The first division of 
proteases is made based on the active site catalytic residue.  Aspartate proteases catalyze 
hydrolysis through an aspartic acid residue side chain in complex with a water molecule.  
Metallo-proteases contain a metal cation, for example zinc, which complexes with a 
water molecule, rendering the water molecule nucleophilic enough to perform the 
hydrolysis.  Serine proteases catalyze hydrolysis through reaction of the serine side chain 
hydroxyl moiety with the substrate carbonyl.  Threonine and tyrosine proteases react 
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similarly to serine proteases.  Lastly, cysteine proteases catalyze peptide bond hydrolysis 


























Each of these types of proteases is further partitioned into clans based on the 
overall structural fold.  The clans are given the names AX, SX, MX, and CX, with the 
first letter delineating the catalytic residue.  The second letter is arbitrary, and divides the 




Protease Nomenclature.  Substrate peptides bind with proteases along the active site 
cleft.  The substrate residue side chains interact with various enzyme pockets on both 
sides of the scissile amide bond.  Proteases have varying substrate sequence specificity 
based on the size, shape, and position of these subsite pockets.  Protease nomenclature 
was developed by Schecter and Berger in 1967 and can be seen in Figure 1.2.4  This 
system allows for clear discussion of protease active site pockets and substrate residues, 
as well as their interaction with each other.  All protease subsites and substrate residues 
are named based on their proximity to the scissile bond.  The enzyme pockets that 
interact with substrate residue side chains are named S1, S2, S3, and so on increasing 
from the scissile bond towards the N-terminus of the substrate.  The enzyme subsites 
towards the C-terminus are named S1’, S2’, S3’, and so on, increasing away from the 
scissile bond.  Substrate and inhibitor amino acid residues are named P1, P2, P3, and so 
on, increasing away from the scissile bond towards the N-terminus.  The C-terminal 
residues are names P1’, P2’, P3’, and so on, increasing away from the scissile bond.   
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Cysteine Proteases.  Cysteine proteases catalyze hydrolysis through reaction of the 
cysteine thiol with the substrate amide carbonyl, as shown in Figure 1.3.  The thiol is 
rendered nucleophilic through acid/base coordination with a histidine imidazole ring, 
which constitutes the catalytic dyad.  In some proteases a third residue is involved in the 
positioning of the histidine residue, in which case a catalytic triad exists.  The thiol 
attacks the carbonyl carbon generating a tetrahedral oxyanion intermediate.  This 
intermediate is generally stabilized through interaction with an oxyanion hole in the 
active site containing positively charged residues.  The oxyanion then collapses back to a 
carbon-oxygen double bond, cleaving the amide bond and releasing the C-terminal end of 
the substrate, leaving the acylated enzyme.  The N-terminal end of the substrate is then 
hydrolyzed from the cysteine residue by a water molecule, regenerating the active 

















































Clan CA Proteases and Specificity.  Most cysteine proteases are members of the clan 
CA or the papain family of proteases.  Clan CA cysteine proteases have a deep and 
narrow active site cleft.  The representative protease of this class is papain. 
 Papain.  Papain is the most extensively studied protease, and the first one for 
which a crystal structure was determined.5  Papain is isolated from the tropical papaya 
fruit.  Papain is considered to have a broad specificity relative to other cysteine proteases.  
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The S2 subsite mainly determines the substrate specificity.5  Papain prefers bulky non-
polar side chains in the S2 subsite.5  The S1 subsite will accommodate a wide variety of 
residues, with a small preference for Arg or Lys.5  The S1’ subsite has a very broad 
specificity.5 
 Calpains.  The calpains are members of the clan CA which require Ca2+ for 
protease activity.  They are ubiquitous mammalian enzymes believed to be involved in 
neurodegeneration.6  There are as many as 10 calpains, however the major forms present 
in mammals are calpain I and calpain II, which require µM and mM concentrations of 
Ca2+ for activation, respectively.7  The calpains exist in an inactive form in the absence of 
Ca2+, with the active site closed and a loop blocking the binding of a substrate.  Calpains 
bind Ca2+ at multiple binding sites, causing a conformational change which opens the 
active site and swings the loop away.8  Calpains have narrow specificity, with the 
preference determined by the S2 subsite.  Calpains prefer an S2 Leu or Val residue.9  The 
S1 subsite of the calpains can accommodate a range of aromatic and branched or 
unbranched aliphatic side chains.10 
 Cathepsin B.  Cathepsin B is a lysosomal cysteine protease which is implicated in 
muscular dystrophy, bone resorption, pulmonary emphysema, and tumor metastasis.11  
Cathepsin B displays an S2 specificity for Arg due to a Glu residue in the S2 pocket, 
however it will also tolerate hydrophobic residues in this position.12  Generally, 
hydrophobic residues are well tolerated in the S1 and S3 subsites.11  Cathepsin B is also 
known to bind inhibitors with large hydrophobic sequences in the S1’ to S2’ region.11 
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Clan CD Proteases and Specificities.  Clan CD is a much smaller group of proteases but 
contains some very important members.  Clan CD proteases tend to have a wider, flatter 
active site cleft than clan CA proteases.  Clan CD protease specificity is generally 
determined by the S1 subsite. 
 Caspases.  Caspases compose the larger portion of clan CD proteases.  As many 
as 11 human caspases have been identified.13  Caspases are involved in cytokine 
processing, apoptosis, and inflammation.14  All caspases require a P1 Asp residue in 
substrates and inhibitors for efficient binding.14  Most caspases recognize a tetrapeptide 
sequence in the non-prime side of substrates and inhibitors.14  Differences in tetrapeptide 
preferences provide modest differentiation between caspases. 
 Gingipains.  Gingipains R and K are bacterial proteases isolated from 
Porphyromonas gingivalis and are important virulence factors in the progression of 
periodontitis.15  The specificity of the gingipains is determined almost exclusively by the 
S1 subsite.15  Gingipains R and K have a stringent requirement for a P1 Arg and Lys, 
respectively.  Both gingipains accept a wide variety of amino acid side chains in the S2 
position.15 
 Clostripain.  Clostripain is a cysteine protease isolated from the Gram-positive 
bacterium Clostridium hystolyticum, which is associated with gas gangrene syndrome.  
Clostripain, like other clan CD proteases, determines its specificity by the S1 pocket.16  
Clostripain prefers P1 Arg or Lys residues, with a slight preference for Arg over Lys.16   
 
Inhibitor Design.  Inhibitors for cysteine proteases usually involve a combination of a 
peptide sequence preferred by the target protease along with a “warhead” moiety.  The 
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peptide sequence binds with the protease active site, while the warhead reacts either 
reversibly or irreversibly with the active site cysteine thiol.  When a lead compound 
inhibitor is discovered, the structure is usually refined through SAR studies to find the 
most potent and selective inhibitor analog.  Reversible inhibitor warheads include 
aldehydes, α-ketoamides, α-ketoesters, and α-ketoacids.  These inhibitors interact with 
the protease active site, forming the tetrahedral intermediate, but are eventually 
hydrolyzed, regenerating enzyme and inhibitor in an equilibrium reaction.  Irreversible 
inhibitors of cysteine proteases have been extensively reviewed by Powers et al,17 and 
include halomethylketones, epoxides, vinyl sulfones, and acyloxymethylketones.  These 
inhibitors inactivate their protease target through alkylation of the active site cysteine 
thiol, permanently disabling enzyme function.  As more and more protease crystal 
structures become available, inhibitor design can be directed through modeling and 
docking of potential inhibitors in the enzyme active site.  There are also efforts to replace 
the peptide portion of inhibitors with a peptidomimetic in order to make an inhibitor that 
is more bioavailable and less susceptible to metabolic elimination.  Such inhibitors would 
have increased therapeutic value. 
 
Irreversible Inhibitor Kinetics.  Irreversible inhibitors react with their target enzymes 
through the formation of a non-covalent enzyme-inhibitor intermediate E·I, where KI is 
the dissociation constant.  A covalent bond is then formed yielding E-I, with k2 
designating the first-order rate constant of the bond formation.   
 
KI





In 1962 Kitz and Wilson18 developed a method for the determination of KI and k2 
by incubating enzyme with a large excess of inhibitor and subsequently diluting the 
sample into a buffer solution containing an appropriate peptide substrate with measurable 
cleavage properties. The residual enzyme activity vt is hereby measured at time t of the 
incubation.  This method is described by the following equation 
 
ln(vt/vo) = -kobst 
 
where vo is the initial rate of substrate hydrolysis in the absence of inhibitor and kobs is 
the pseudo-first order rate constant.  The parameter kobs is defined by the following 
equation: 
 
kobs = k2[I]/(KI + [I]) 
 
When inhibitor concentration is less then 10-fold excess of enzyme concentration, 
the pseudo-first order rate constant no longer accurately describes the inhibition rate, as 
the inhibitor concentration can no longer be assumed to be a steady state.  In this case, 
second order kinetics must be applied as defined in the following equation: 
 
k2ndt = [1/(i – e)]ln[e(i – x)/i(e – x)] 
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where i and e are initial inhibitor and enzyme concentrations, respectively, and e – x and 
i-x account for the changing enzyme and inhibitor concentration over the course of the 
experiment.   
 Faster reacting inhibitors are logistically difficult to measure by the incubation 
method, and in this case the Progress Curve Method provides a convenient alternative.  
Developed by Tian and Tsou,19 the progress curve method involves monitoring the 
substrate hydrolysis of the enzyme in the presence inhibitor over time until the enzyme is 
completely inhibited.  In this method the substrate and inhibitor compete for the enzyme 
active site, which slows down the inhibition reaction.  This method follows an 
exponential time course where the accumulated substrate hydrolysis product P 
approached a limited concentration [P]∞: 
 




ln([P] ∞ - [P]t) = -A[I]t 
 
where A is the apparent rate constant of inhibition, and can be determined by the plot of 
ln([P] ∞ - [P]t) versus time.  The apparent rate constant is converted to a second order rate 
constant using the following equation: 
 
k2 = A(1 + [S]/KM) 
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This conversion accounts for the slowing of inhibition due to substrate competition.  The 
progress curve method is convenient for fast inhibitors, and for enzymes, such as calpain, 
which require high enzyme concentrations for hydrolysis detection, and therefore high 




AZA-PEPTIDE EPOXIDE AND EPOXIDE INHIBITORS OF CALPAINS AND 





 Calpains are calcium activated ubiquitous cysteine proteases that are members of 
the clan CA papain family.  Calpains I and II are distinguished by the requirement of 
micromolar and millimolar concentrations of calcium respectively. A current hypothesis 
is that cellular injury leads to elevated intracellular calcium and provokes the pathologic 
activation of calpains.20  The activation of calpains is believed to be responsible for the 
cell death and axonal degeneration seen in ischemic stroke,21 spinal cord injury,22 closed 
head injury,23 and Wallerian degeneration.24  The calpains are also shown to be involved 
in a number of diseases that involve neurodegeneration, including Alzheimer’s 
disease,25,26 Parkinson’s disease,27 muscular dystrophy,28 and diabetes.29,30  Calpain 
inhibitors have been shown to be therapeutic agents against many conditions including 





Calpain Structure.  The structure of calcium-free, inactive calpain I has been solved,7 as 
well as the crystal structure of calcium-bound, active calpain I.8  The authors mainly 
investigated the mechanism by which Ca2+ binding induces structural repositioning 
around the active site to produce proteolytic activity, however they did note that the 
active site of calpain aligned very well with the active site of papain.  A more recent 
paper by the same group investigates the active site structure of calpain through its 
interactions with the aldehyde inhibitor leupeptin and the epoxide inhibitor E64.33  The 
authors conclude that while the active sites of calpain and papain are highly similar, the 
active site cleft of calpain is deeper and narrower, requiring substrates and inhibitors to 
adopt an extended conformation.  There are also two mobile loops present in calpain on 
each side of the active site cleft, which seem to both widen the active site for inhibitor 
binding and to swing around a bound inhibitor.  The S1 and S2 pocket structures of 
calpain are highly conserved with papain, however the S3 subsite of calpain seems to be 
more solvent exposed.  This S3 difference could be an artifact of the truncated protease 
core of calpain used in this study.  The publishing of these structure studies will lead to 
greater structure-based design of calpain inhibitors in the future. 
 
Calpain Inhibitors.  Calpastatin is an endogenous polypeptide that specifically inhibits 
calpain.  This polypeptide is present in vivo and is part of a calpain activity regulatory 
system.  Calpastatin is the only specific calpain inhibitor known, and has no activity 
toward papain and other cysteine proteases.  Calpastatin is a large polypeptide that binds 
calpain at an allosteric region, inducing a conformation change that renders calpain 
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inactive.  The fact that calpastatin inhibits through a mechanism that does not include the 
calpain active site results in selectivity.    
 Synthetic inhibitors developed for calpains have been well reviewed and include 
peptide aldehydes, α-ketoamides, halomethylketones, and acyloxymethylketones.9,17  
While some of these inhibitors are potent deactivators of calpain, few are selective 
inhibitors for calpain over other cysteine proteases.  An overview of several potent 




Table 2.1.  Representative Calpain Inhibitors From the Literature. 
No. Inhibitor Calpain 1 Inhibition Ref 
 Irreversible   
1 HO-EPS-Leu-(CH2)4-NH-C(=NH)-NH2  (E64) kobs/[I] =     7,450 M-1s-1 34 
2 HO-EPS-Leu-(CH2)4-NH-CO2-benzyl  (EP460) kobs/[I] =   15,000 M-1s-1 self tested 
3 Z-Leu-Leu-Phe-CH2F kobs/[I] = 290,000 M-1s-1 9 
4 Z-Leu-Phe-CH2OPO(O-2-methylbenzyl)2 kobs/[I] = 365,000 M-1s-1 9 
5 Z-Leu-Leu-Tyr-VS-phenyl kobs/[I] =   24,300 M-1s-1 9 
 Reversible   
6 Z-Val-Phe-H IC50 =          0.01 µM 
9 
7 Z-Leu- Abu-CONH-(CH2)3-morpholino  
(AK295) 





 The ketoamide calpain inhibitor AK295, Figure 2.1, has been studied extensively 
in cells and has been shown to protect cells from death following brain ischemia.23,36  We 
have recently demonstrated that AK295 has the ability to inhibit calpain activity in PC12 
cells following calpain activation by paclitaxel.37  However, AK295 has a charged 
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morpholino group which could limit its potency in cells.  Because of these issues, we 












































Cal I kobs/[I] = 7,000 M
-1s-1AK295 (7)
Cal II KI = 0.041µM
 




 The naturally occurring epoxide inhibitor E64, Figure 2.1, isolated from 
Aspergillus japonicus is known to be an general inhibitor of clan CA proteases.38  The 
epoxide analog EP460 is the most potent epoxide inhibitor for calpain in the literature (k 
= 15,200 M-1s-1).34  The epoxides inhibit through an irreversible reaction with the active 
site cysteine thiol, resulting in permanent alkylation of the catalytic cysteine residue.   
 The mechanism of inhibition by epoxide inhibitors can be seen in Figure 2.2.  The 
cysteine thiol can theoretically attack on either the C2 or C3 carbon of the epoxide, 
resulting in the epoxide ring opening.  Crystal structures of clan CD proteases (caspase-3, 
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SARS coronavirus main protease) with epoxides synthesized in the Powers laboratory 









 Epoxide inhibitors have several advantages over other types of calpain inhibitors.  
Epoxides are generally not as reactive as halomethylketones and aldehydes, so they have 
the potential to be more selective towards a single target and could cause fewer toxicity 
problems in vivo. Since epoxide inhibitors are irreversible and the enzyme is permanently 
inactivated, this class of inhibitors could be delivered less frequently than reversible 
transition-state inhibitors, which are only effective until they are cleared from the 
circulation.  Epoxides were put through human trials in Japan in the 1980’s for muscular 
dystrophy, and while they were shown to be non-toxic, the particular inhibitors tested 


























The Aza-Peptide Epoxide Design.  The Powers laboratory has recently developed the 
aza-peptide epoxide warhead for clan CD proteases with great success.43  The aza-peptide 
epoxide design involves replacing the α-carbon of an amino acid residue with a nitrogen, 
and using this nitrogen as a connection point for the epoxysuccinate moiety.  An example 
of an aza-peptide epoxide can be seen in Figure 2.3.  Some possible advantages of the 
aza-peptide epoxide design include: a) the loss of stereochemistry at the aza-amino acid 
residue resulting in a planar geometry, b) the ease of synthesis of the amide bond between 
the nitrogen of the aza-residue and the epoxysuccinate, c) the ability to easily extend the 
inhibitor to the prime side, varying prime side residues to create a more potent and 

















 An initial design to create aza-peptide epoxide inhibitors of calpain included aza-
peptide epoxides of the sequences Z-Leu-AHph and Z-Leu-ALeu as seen in Figure 2.4.  
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The Leu residue was chosen because calpain requires a P2 leucine.  The ALeu and AHph 
were also chosen to be compatible with calpain. The inhibitors were synthesized with an 
ethyl ester in the P1’ position for simplicity of synthesis and structure.  These inhibitors 
were also tested with the clan CA enzymes cathepsin B and papain, which have potential 


















R = isobutyl (ALeu)
R = phenylethyl (AHph)
 




 In another design, the aza-peptide epoxide analog of EP460 was explored as a 
potential calpain inhibitor, as seen in Figure 2.5.  EP460 is the most potent of the known 
epoxide inhibitors for calpain.  The aza-version of EP460 would be a “reverse” inhibitor 
compared to the first design, given that EP460 binds in the active site in the C → N 
peptide direction, opposite of the N → C direction of the previous design.  The 
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conversion of the inhibitor to an aza-peptide involved the substitution of a nitrogen atom 
for the Leu α-carbon.  This modification is expected to alter the geometry of the inhibitor 























Epoxide Stereochemistry.  The epoxide moiety has two stereocenters, with the 
possibility of 4 different epoxide isomers: two “trans” isomers (2S, 3S and 2R, 3R) and 
two “cis” isomers (2S, 3R and 2R, 3S).  The literature on epoxide inhibitors comes to the 
consensus that the trans (2S, 3S) isomer tends to be the most potent for clan CA enzymes.  
However, due to our unique design, we synthesized versions of the inhibitors containing 
the two trans isomers stereospecifically, along with a version containing a mixture of the 
cis isomers, with the idea that if the cis isomers were potent they could also be 






 The synthesis of the AHph derivatives is shown in Figure 2.6.  The methyl ester 
of Z-Leu-OH was synthesized by treatment with SOCl2 in MeOH.  Z-Leu-OMe was 
treated with hydrazine to yield 10.  Z-Leu-NHNH2 (10) was condensed with 
phenylacetaldehyde to yield the hydrazone 11.  The hydrazone was reduced with 
NaBH3CN under acidic conditions to yield the hydrazide 12.  The hydrazide was coupled 
to the epoxysuccinates by the EDC/HOBT coupling method to yield the final inhibitors 
13a-c, each differing in epoxide stereochemistry.  The stereospecific epoxysuccinates 
were synthesized by method of Mori,44 starting from the D or L diethyltartarate.  The 
ALeu inhibitors were synthesized similarly, substituting isobutyraldehyde for 













































Figure 2.6.  Synthesis of Aza-Peptide Epoxide Inhibitors for Calpains. Reagents and 
conditions: a) SOCl2, MeOH.  b) 10 eq NH2NH2, THF.  c) phenylacetaldehyde, THF.  d) 





The synthesis of the aza-EP460 derivatives can be seen in Figure 2.7.  Boc-
hydrazine was condensed with isobutyraldehyde followed by reduction with NaBH3CN 
under acidic conditions to yield 15.  Carbonyldiimidazole was treated with N-
(benzyloxycarbonyl)-butane-1,4-diamine, synthesized by method of Atwell and Denny,45 
followed by 15 to yield the urea 16.  The Boc protecting group was removed by treatment 
with 4 N HCl in EtOAc, followed by mixed anhydride coupling with ethyl (2S, 3S)-
oxirane-2,3-dicarboxylate, which is synthesized by method of Mori.44  In the final step 

























































Figure 2.7.  Synthesis of Aza-EP460 Inhibitors for Calpains.  Reagents and conditions: a) 
isobutyraldehyde, EtOH, reflux.  b) NaBH3CN, p-TsOH, THF.  c) CDI, NMM, 
NH2(CH2)4NH-Cbz, CH2Cl2.  d) 4N HCl in EtOAc.  e) ethyl (2S,3S)-oxirane-2,3-




Results and Discussion 
 
 The inhibitory results of the first design of aza-peptide epoxide compounds can be 
seen in Table 2.2.  Clearly, these compounds are poor inhibitors of calpain, cathepsin B, 
and papain, with all inhibition rates being less than 10 M-1s-1.  The epoxide 
stereochemistry preference seems to be 2S,3S > 2R,3R > cis, while the ALeu sequence is 
preferred over the AHph.  It seems that the change in geometry afforded by the aza-
residues is not tolerated by these clan CA proteases in this inhibitor design.  This is 
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interesting given the fact that inhibitors of the same design with peptide sequences 
targeted towards clan CD proteases (caspases, gingipains, legumain) easily have 
inhibition rates in the millions.43  These aza-peptide epoxide inhibitors designed for 
calpain demonstrate that this inhibitor design selectively inhibits clan CD proteases over 
the larger populated clan CA.  While these inhibitors are not very potent and show little 
promise of being used in further calpain studies, this discovery demonstrates that the aza-




Table 2.2.  Inhibition of Clan CA Proteases by Aza-Peptide Epoxides. 













19aa Z-Leu-ALeu-EP-COOEt 2S,3S 8.6 1.8    10 
19b Z-Leu-ALeu-EP-COOEt 2R,3R 1.4 NI 6.7 
19c Z-Leu-ALeu-EP-COOEt cis 1.9 NI 0.4 
13a Z-Leu-AHph-EP-COOEt 2S,3S 2.3 0.7 5.7 
13b Z-Leu-AHph-EP-COOEt 2R,3R 2.1 NI 2.2 
13c Z-Leu-AHph-EP-COOEt cis 1.1 NI 1.0 




 Inhibition data for calpain I, cathepsin B, and papain with the aza-EP460 analog 
inhibitors can be seen in Table 2.3.  All of these compounds are significantly less potent 
than the parent EP460 compound, however the inhibition rates are 100-fold higher for 
this series of compounds compared with the previous design.  The epoxide with the 
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(2S,3S) epoxide stereochemistry and the P1’ carboxylic acid (18a) displayed the most 
potency.  While these aza-EP460 compounds are modest inhibitors of calpain, cathepsin 
B, and papain, it seems that clan CA enzymes do not accept the change in geometry 




Table 2.3.  Inhibition of Clan CA Proteases by Aza-EP460 Analogs. 
















       kobs/[I] (M-1s-1) 
No. R Stereochemistry Calpain I   Cathepsin B      Papain 
18a HO         2S,3S           1,450 ±  240        1,220 ± 390    1,000 ± 30 
17a EtO         2S,3S        NI                      8.0                   NI 
18b HO         2R,3R        NI           NI                    NI 
17b EtO         2R,3R        NI                      NI          NI 




 One of the major differences in the clan CA and CD active sites is that clan CA 
enzymes have a deeper, narrower active site cleft, while the active site of clan CD 
enzymes is more shallow and wide.  The shallower, wider active site of the clan CD 
proteases seems to allow for the aza-peptide epoxides to bind productively, while the 
narrower active site of clan CA proteases prohibits productive binding.  Hence, we have 
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discovered one of the few types of inhibitor warheads which discriminates between clans 
of cysteine proteases.  This discovery strengthens the importance of the potent aza-
peptide epoxide inhibitors that the Powers laboratory has produced for the caspases and 
other clan CD proteases. 
 
 
New Epoxide Inhibitor Design 
 
With the previous results in mind, the focus of the design was shifted away from 
the aza-peptide epoxide, to design non-aza epoxide inhibitors by modifying the “C-
terminal” end of the inhibitor EP460.  The goal of this design is not a new warhead for 
calpain inhibitors, as the previous work, but to determine the best group for the P3-P4 
region of the EP460 inhibitor to create a more potent and selective inhibitor.  Calpain has 
a stringent requirement for Leu or Val in the P2 position of substrates and inhibitors.  As 
demonstrated by EP460, calpain seems to prefer a larger aromatic group in the P3/P4 
region.34  Therefore, we designed a series of inhibitors with various aromatics and 
various spacings to replace the benzyl group of EP460, as seen in Figure 2.8.  The goal 
was to discover inhibitors with greater inhibitory potency towards calpain, while 


















Cal I kobs/[I] = 15,200 M
-1s-1  






The synthesis of the new EP460 analog compounds can be seen in Figure 2.9.  
Diaminobutane was selectively protected on one amine with the Boc protecting group to 
yield 20.  The aromatic side chains were added through reaction with various isocyanates, 
or through mixed anhydride peptide couplings to give 21a-i.  The Boc group was then 
removed with TFA, and Boc-leucine was coupled through mixed anhydride conditions to 
the resulting amine yielding 22a-i.  The Boc group was again removed with TFA, and the 
epoxysuccinate was introduced by mixed anhydride coupling giving 23a-i.  In the final 
step the ethyl ester was hydrolyzed under basic conditions to yield the final compounds 































































Figure 2.9.  Synthesis of Epoxide Inhibitors Which Are Analogs of EP460.  Reagents and 
conditions: a) (Boc)2O, dioxane.  b) R-N=C=O, CH2Cl2 or HOOC-R, IBCF, NMM. c) 
TFA, CH2Cl2.  d) Boc-Leu-OH, IBCF, NMM, CH2Cl2.  e) ethyl (2S,3S)-oxirane-2,3-
dicarboxylate, IBCF, NMM, CH2Cl2.  f) NaOH, EtOH. 
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Results and Discussion 
 
The kinetic inhibition results can be seen in Table 2.4.  Most of the inhibitors 
synthesized were in the same potency range with calpain I and II as EP460, with a few 
being more potent.  The best inhibitors for the calpains incorporated the 1-naphthyl 
moiety (24f, 24h).  The benzyl urea compound (24b) and the phenoxyphenyl urea (24i) 
were also potent inhibitors.  The EP460 analog containing the ethyl ester (23a) was a 
significantly less potent inhibitor with all of the enzymes, demonstrating the importance 
of the carboxylic acid for inhibitor binding.  Generally, the best inhibitors for calpain I 
and calpain II were the same, however the inhibitor potency with calpain II was 2-fold 
greater than calpain I.  It is worth noting that while some of the inhibitors demonstrated 
greater inhibitory potency with calpain than EP460, all of the new inhibitors are 
significantly less potent than EP460 with cathepsin B and papain.  A few of the inhibitors 
(24b, 24c, 24f) are even more potent with calpain II than with cathepsin B, which has 
been a difficult property to attain in inhibitors.  Since papain is not a human protease, 
selectivity over papain is inconsequential for our purposes of drug development.  We 











































     
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

















































































































































   









































































































































































































































































































































































































































Calpain activation has been shown to be an important step in the pathology of 
several neurological diseases.  Calpains, when activated, can degrade neurons and axons, 
causing symptoms of numbness, weakness, and even abnormalities of cognition.  We 
collaborated with Dr. Jonathan Glass at Emory University in order to test our calpain 
inhibitors in a model of calpain-mediated neurodegeneration.  This model uses rat 
pheochomocytoma (PC12) cells to test the ability of calpain inhibitors to penetrate cell 
membranes and inhibit intracellular calpain activity.  PC12 cells are considered "neuron-
like", and so are relevant to testing for efficacy in nervous system diseases.  In this assay 
PC12 cells are treated with the chemotherapy drug paclitaxel, which creates an increase 
in intracellular calpain activity. Our calpain inhibitors were introduced into the cell 
culture media before treatment with paclitaxel in order to determine if these compounds 
could cross the cell membrane and inhibit intracellular calpain activity. 
The results of these experiments are shown in Table 2.4 and reported as % 
inhibition of calpain relative to the amount of calpain activity with paclitaxel alone.  
Several of the epoxide inhibitors proved to be more potent calpain inhibitors than the α-
ketoamide AK295, our benchmark calpain inhibitor.  EP460 (24a) was the most potent 
inhibitor in this assay, along with the ethyl ester derivative 23a.  Although the 23a was a 
much weaker inhibitor in the non cell based kinetic studies, the ethyl ester is hydrolyzed 
by esterases in cells, generating the more potent acid form 24a.  It is therefore reasonable 
that 23a and 24a have differing potencies in non-cell based assays, but inhibit similarly in 
cells. The methoxyphenyl and phenoxyphenyl inhibitors 24d and 24i were the most 
potent of the new inhibitors in this assay.  It is interesting to note that 24d and 24i were 
not the most potent inhibitors in the non-cell based assays.  These inhibitors may be 
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better able to cross the cell membrane to inhibit intracellular calpain activity.  These 
experiments demonstrate that our epoxide inhibitors are able to cross cell membranes and 
efficiently inhibit calpain in cell culture, which is an important step toward their 





The aza-peptide epoxide designs were unable to provide potent inhibitors for 
calpain and the other clan CA enzymes.  This is a very important discovery given the 
potency of this design for the clan CD enzymes.  These compounds proved that the aza-
peptide epoxide warhead is specific for clan CD proteases, which is a rare characteristic 
of warheads.  The difference in the active site cleft between these two clans of proteases 
is probably responsible for the different aza-peptide epoxide potencies. 
We were successful in the development of new epoxide inhibitors for calpains I 
and II based on the inhibitor EP460.  By varying the P3-P4 region of EP460 we were able 
to discover inhibitors that were more potent and selective for the calpains than EP460.  
The increased selectivity for the calpains over cathepsin B is the most significant 
discovery, given that specific calpain inhibitors have been elusive.  These epoxide 
inhibitors were also able to inhibit calpain activity in a cellular assay, which demonstrates 
that they are bioavailable enough to cross cell membranes and reach the calpain where it 





Enzyme Assays.  Calpains I and II, cathepsin B, and papain inhibition rates were 
determined using the progress curve method.  The calpains and cathepsin B activities 
were determined using the appropriate fluorogenic peptide 7-amino-4-methylcoumarin 
substrates (AMC, excitation λ = 360 nm, emission λ = 405 nm), while papain activity 
was determined using the appropriate p-nitroaniline absorbance substrate.  The 
fluorescence and absorbance was detected with a Tecan Spectraflour Microplate Reader 
(Tecan US, Research Triangle Park, NC).   
Calpains I and II.  Calpains I and II were obtained from Calbiochem, (LaJolla, 
CA) and stored at –78 oC in a storage buffer of 50 mM Tris-HCl, 5 mM EDTA, 5 mM β-
ME, 100 mM NaCl, 40% glycerol, pH 7.8 at a concentration of 1.14 mg/mL.  The kinetic 
assay buffer is 50 mM HEPES, 10 mM cysteine, 5 mM CaCl2, pH 7.5.  The inhibitor 
dissolved in DMSO was diluted with kinetic assay buffer containing the substrate Suc-
Leu-Tyr-AMC (final concentration [S] = 1.30 mM).  At t = 0 s, the enzyme in storage 
buffer was added to the mixture (calpain I [E] = 0.117 µM, calpain II [E] = 0.117 µM, [I] 
= 0.42 µM to 84 µM).  The reaction was monitored over 10 min. by following the change 
in fluorescence at 465 nm.  Inhibition rates were performed in duplicate, and the error 
ranges are reported. 
Cathepsin B.  Cathepsin B was purchased from Athens Research Technologies 
(Athens, GA) in a solution of 20 mM NaAc, 1 mM EDTA, pH 5.0 at a concentration of 
31.2 µM.  A 100-fold dilution of the enzyme in the kinetic assay buffer 0.1 M potassium 
phosphate, 1.25 mM EDTA, 0.01% Brij, 1 mM DTT, pH 6.0 was activated for 1 hour at 0 
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oC.  The inhibitor dissolved in DMSO was diluted with kinetic assay buffer containing 
the substrate Z-Arg-Arg-AMC (final concentration [S] = 0.40 mM).  At t = 0, the 
activated enzyme was added to the mixture ([E] = 5.23 nM, [I] = 0.42 µM to 0.84 µM).  
The reaction was monitored over 20 min. by following the change in fluorescence at 465 
nm.  Inhibition rates were performed in duplicate, and the error ranges are reported. 
Papain.  Papain was purchased from Sigma Chemical Co. (St. Louis, MO) as a 
purified powder and stored at –20 oC in a stock solution of the kinetic assay buffer 50 
mM HEPES, 3 mM DTT, 2.5 mM EDTA, pH 7.5 at a concentration of 51.7 µM.  For the 
assay a 100-fold dilution of the stock enzyme solution in kinetic assay buffer was allowed 
to activate at 0 oC for 30 min.  The inhibitor dissolved in DMSO was diluted with assay 
buffer containing the substrate Z-Phe-Arg-pNA (final concentration [S] = 0.550 mM).  At 
t = 0, the activated enzyme was added to the mixture (final [E] = 8.67 nM, [I] = 21 nM to 
42 nM).  The reaction was monitored over 20 min. by following the change in absorbance 
at 405 nm. Inhibition rates were performed in duplicate, and the error ranges are reported. 
PC12 Cellular Assay with Paclitaxel.  PC12 cells were cultured for 24 hours and 
then treated with 200 ng/mL paclitaxel (Sigma) and 50 µM inhibitor in DMSO for 24 
hours.  After washing with PBS, the cells were resuspended in 8 mL KRH (125 mM 
NaCl, 5 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 2 mM CaCl2, 6 mM glucose and 25 
mM HEPES, pH 7.4) containing 50 µM inhibitor.  To 2 mL of this solution was added 
100 µL Suc-Leu-Leu-Val-Tyr-AMC to a final concentration of 45 µM.  The cells were 
incubated at 37 oC for 15 minutes, and the reaction was terminated by the addition of 100 
µL of 0.4 N HCl.  The cells were sonicated for 10 seconds and centrifuged for 5 minutes.  
The supernatant (200 µL) was transferred to a 96 well plate and fluorescence measured at 
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excitation 355 nm and emission 460 nm.  The experiment was duplicated 6 times per 
inhibitor, and the average percent inhibition and standard deviations were reported. 
Materials and Methods.  Amino acids and their analogs were purchased from 
Bachem Biosciences Inc. (King of Prussia, PA).  Column chromatography was carried 
out on flash silica gel, 32-63 u, 60 Å, purchased from Sorbent Technologies (Norcross, 
GA).  The 1H NMR spectra were obtained using a Varian Mercury Vx 400 MHz 
spectrometer.  Electrospray ionization (ESI), fast-atom bombardment (FAB) and high-
resolution mass spectrometry were performed using Micromass Quattro LC and VG 
Analytical 70-SE instruments by Georgia Tech MS laboratory personnel.   
 
Z-Leu-OMe.  Z-Leu-OH (3.05 g, 11.3 mmol) was dissolved in methanol and 
cooled to -78 oC in a dry ice/acetone bath.  Thionyl chloride (5.25 g, 34.0 mmol) was 
added dropwise to the solution, and the reaction was allowed to warm to room 
temperature and stir overnight.  The reaction was concentrated to yield Z-Leu-OMe 
quantitatively without further purification. 
Z-Leu-NH-NH2.  Z-Leu-OMe (3.00 g, 10.8 mmol) was dissolved in methanol (40 
mL).  Hydrazine (3.45 6g, 108 mmol) was added to the solution, and the reaction was 
stirred overnight.  The reaction was concentrated under vacuum and crystallized in ether 
to yield Z-Leu-NH-NH2 as a white solid quantitatively.   
Z-Leu-NH-N=CHCH2-C6H5.  Z-Leu-NH-NH2 (3.00 g, 10.8 mmol) was 
dissolved in dry THF (40 mL) with molecular sieves.  Phenylacetaldehyde (1.42 6g, 11.9 
mmol) was added dropwise to the solution, and the reaction was allowed to stir for 3 hrs.  
The molecular sieves were removed by filtration, the reaction concentrated, and the crude 
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product purified by column chromatography (5% MeOH in CH2Cl2) to yield Z-Leu-NH-
N=CHCH2-C6H5 (2.568 g, 62% yield). 
Z-Leu-NH-NH-CH2CH2-C6H5. Z-Leu-NH-N=CHCH2-C6H5 (0.666 g, 1.75 
mmol) was dissolved in dry THF (50 mL).  NaBH4 (0.330 g, 8.74 mmol) was added to 
the solution, and the reaction was allowed to stir for 90 min.  The reaction was 
concentrated and the residue dissolved in CH2Cl2 and washed with sat. NaCl.  The 
organic layer was concentrated, and the residue crystallized from CH2Cl2/hexanes to 
yield a white solid.  The solid was purified by column chromatography (1:2 
EtOAc:CH2Cl2) to yield Z-Leu-NH-NH-CH2CH2-C6H5 (0.131 g, 19% yield).  1H NMR 
(CDCl3): 0.83-0.95 (d, 6H), 1.40-1.45 (m, 1H), 1.59-1.70 (m, 2H), 2.72-2.80 (t, 2H), 
3.01-3.15 (m, 2H), 4.01-4.12 (m, 1H), 4.93-5.01 (s, 1H), 5.08-5.11 (s, 2H), 7.13-7.22 (s, 
1H), 7.22-7.42 (m, 10H). 
cis-3-(N2-(N-Benzyloxycarbonylleucyl)-N1-(2-
phenethylhydrazinocarbonyl))oxirane-2-carboxylic acid ethyl ester (Z-Leu-AHph-
cis-EP-COOEt).  General EDC/HOBT Coupling Method.  To a solution of cis-Ethyl-
2,3-oxirane-dicarboxylate (180 mg, 1.125 mmol) in DMF (9 mL) was added HOBT (154 
mg, 1.135 mmol). Z-Leu-NH-NH-CH2CH2-C6H5 (415 mg, 1.083 mmol) was added to the 
reaction followed by EDC (229 mg, 1.195 mmol) and the reaction was allowed to stir 
overnight.  The reaction was concentrated in vacuo, and the residue was taken up in 
EtOAc and washed successively with 2% citric acid, sat. NaHCO3, water, and sat. NaCl.  
The organic layer was concentrated and purified by column chromatography (2.5% 
MeOH, 25% EtOAc, 72.5% CH2Cl2) and recrystallized from EtOAc/hexanes to yield Z-
Leu-AHph-cis-EP-COOEt (177 mg, 20%).  1H NMR (CDCl3): 0.85-0.96 (d, 6H, J = 6 
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Hz), 1.21-1.35 (t, 3H, J = 6 Hz), 1.48-1.53 (m, 1H), 1.60-1.71 (m, 1H), 2.78-2.88 (t, 2H, 
J = 7 Hz), 3.50-3.52 (d, 2H, J = 4 Hz), 3.58-3.68 (t, 2H, J = 6 Hz), 3.95-4.00 (s, 1H), 
4.19-4.28 (q, 2H, J = 6 Hz), 5.08-5.17 (s, 2H), 7.28-7.40 (m, 10H), 8.20-8.24 (s, 1H), 
8.32-8.39 (s, 1H).  HRMS (FAB) Calcd. For C28H36N3O7: 526.25533.  Observed m/z 
526.25508. 
(2S,3S)-3-(N2-(N-Benzyloxycarbonylleucyl)-N1-(2-
phenethylhydrazinocarbonyl))oxirane-2-carboxylic acid ethyl ester (Z-Leu-AHph-
(2S,3S)-EP-COOEt).  (2S,3S)-Ethyl-2,3-oxirane-dicarboxylate (43 mg, 0.271 mmol) and 
Z-Leu-NH-NH-CH2CH2-C6H5 (100 mg, 0.261 mmol) were reacted following the general 
EDC/HOBT coupling method.  The crude product was purified by column 
chromatography to yield Z-Leu-AHph-(2S,3S)-EP-COOEt (66 mg, 48% yield).  1H NMR 
(CDCl3): 0.82-0.96 (d, 6H, J = 9 Hz), 1.21-1.33 (t, 3H, J = 9 Hz), 1.41-1.50 (m, 1H), 
1.50-1.63 (m, 2H), 2.75-2.82 (t, 2H, J = 6 Hz), 3.58-3.59 (s, 1H), 3.76-3.77 (s, 1H), 3.88-
4.05 (m, 2H), 4.10-4.25 (q, 2H, J = 3 Hz), 4.89-4.96 (d, 1H, J = 8 Hz), 5.08-5.21 (s, 2H), 
7.23-7.40 (m, 10H), 8.02-8.13 (s, 1H).  HRMS (FAB) Calcd. For C28H36N3O7: 
526.25533.  Observed m/z 526.25164. 
(2R,3R)-3-(N2-(N-Benzyloxycarbonylleucyl)-N1-(2-
phenethylhydrazinocarbonyl))oxirane-2-carboxylic acid ethyl ester (Z-Leu-AHph-
(2R,3R)-EP-COOEt).  (2R,3R)-Ethyl-2,3-oxirane-dicarboxylate (43 mg, 0.271mmol) 
and Z-Leu-NH-NH-CH2CH2-C6H5 (100 mg, 0.261 mmol) were reacted following the 
general EDC/HOBT coupling method.  The crude product was purified by column 
chromatography (1:2 EtOAc:CH2Cl2) to yield Z-Leu-AHph-(2R,3R)-EP-COOEt (88 mg, 
64% yield).  1H NMR (CDCl3): 0.81-0.96 (d, 6H, J = 8 Hz), 1.20-1.31 (t, 3H, J = 8 Hz), 
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1.39-1.48 (m, 1H), 1.51-1.63 (m, 2H), 2.78-2.84 (t, 2H, J = 6 Hz), 3.42-3.55 (m, 2H), 
3.58-3.59 (s, 1H), 3.80-3.81 (s, 1H), 3.93-4.08 (m, 1H), 4.12-4.29 (q, 2H, J = 3 Hz), 4.80-
4.85 (s, 1H), 5.08-5.12 (s, 2H), 7.25-7.39 (m, 10H), 7.83-7.94 (s, 1H).  HRMS (FAB) 
Calcd. For C28H36N3O7: 526.25533. Observed m/z 526.25386. 
Z-Leu-NH-N=CHCH(CH3)2.  Z-Leu-NH-NH2 (3 g, 10.6 mmol) and 
isobutyraldehyde (0.85 g, 11.8 mmol) were reacted following the same procedure as Z-
Leu-NH-N=CHCH2-C6H5.  The crude produce was purified by column chromatography 
(10% MeOH in CH2Cl2) to yield Z-Leu-NH-N=CHCH(CH3)2 (1.971 g, 54% yield).   
Z-Leu-NH-NH-CH2CH(CH3)2.  Z-Leu-NH-N=CHCH(CH3)2 (1.971 g, 5.29 
mmol) was reduced with NaBH4 (1.12 g, 52.9 mmol) following the same procedure as Z-
Leu-NH-NH-CH2CH2-C6H5.  The crude product was purified by column chromatography 
(1:2 EtOAc:CH2Cl2) to yield Z-Leu-NH-NH-CH2CH(CH3)2 (0.59 g, 30% yield).  1H 
NMR (CDCl3): 0.83-0.96 (d, 12H), 1.23-1.24 (m, 2H), 1.62-1.78 (m, 4H), 2.60-2.67 (d, 
2H), 4.04-4.16 (s, 1H), 5.10-5.12 (s, 2H), 7.25-7.38 (m, 5H). 
cis-3-(N2-(N-Benzyloxycarbonylleucyl)-N1-
(isobutylhydrazinocarbonyl))oxirane-2-carboxylic acid ethyl ester (Z-Leu-ALeu-cis-
EP-COOEt). The cis-ethyl-2,3-oxirane-dicarboxylate (49 mg, 0.309 mmol) and Z-Leu-
NH-NH-CH2CH(CH3)2 (100 mg, 0.298 mmol) were reacted following the general 
EDC/HOBT coupling method.  The crude product was purified by column 
chromatography (1:2 EtOAc:CH2Cl2) to yield Z-Leu-ALeu-cis-EP-COOEt (58 mg, 41% 
yield).  1H NMR (CDCl3): 0.78-0.93 (m, 12H), 1.20-1.34 (t, 3H, J = 6 Hz), 1.40-1.45 (m, 
2H), 1.61-1.79 (m, 4H), 3.50-3.60 (m, 2H), 4.07-4.14 (q, 2H, J = 7 Hz), 5.03-5.16 (s, 
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2H), 7.26-7.40 (m, 5H).  HRMS (FAB) Calcd. For C24H36N3O7: 478.25533.  Observed 
m/z 478.25729. 
(2R,3R)-3-(N2-(N-Benzyloxycarbonylleucyl)-N1-
(isobutylhydrazinocarbonyl))oxirane-2-carboxylic acid ethyl ester (Z-Leu-ALeu-
(2R,3R)-EP-COOEt). (2R,3R)-Ethyl-2,3-oxirane-dicarboxylate (49 mg, 0.309 mmol) 
and Z-Leu-NH-NH-CH2CH(CH3)2 (100 mg, 0.298 mmol) were reacted following the 
general EDC/HOBT coupling method.  The crude product was purified by column 
chromatography (2.5% MeOH, 25% EtOAc, 72.5% CH2Cl2) to yield Z-Leu-ALeu-
(2R,3R)-EP-COOEt (73 mg, 51% yield).  1H NMR (CDCl3): 0.79-0.98 (m, 12H), 1.20-
1.35 (t, 3H, J = 7 Hz), 1.45-1.53 (m, 4H), 1.62-1.78 (m, 2H), 3.07-3.20 (s, 1H), 3.59-3.60 
(s, 1H), 3.86-3.87 (s, 1H), 4.03-4.16 (q, 2H, J = 6 Hz), 4.16-4.23 (t, 2H, J = 7 Hz), 5.00-
5.09 (d, 1H, J = 7 Hz), 5.09-5.12 (s, 2H), 7.30-7.40 (m, 5H), 8.49-8.53 (s, 1H).  HRMS 
(FAB) Calcd. For C24H36N3O7: 478.25533.  Observed m/z 478.25508. 
Z-NH-(CH2)4-NH2.  To a solution of 1,4-diaminobutane (3 g, 34.0 mmol) in 
water (10 mL) was added bromocresol green.  Methane sulfonic acid (6.08 mL in 9.75 
mL H2O) was added to the solution until the blue to yellow color change occurred.  The 
mixture was diluted with EtOH (20 mL) and alternate drops of benzyl chloroformate 
(4.27 mL in 6.55 mL dimethoxyethane) and potassium acetate (50% in H2O) were added 
to the solution in order to maintain the emerald green color.  The reaction was allowed to 
stir for 1 hr after the green color remained steady.  The reaction was concentrated, taken 
up in water (65 mL), and the solid bis-Z-diaminobutane was isolated by filtration.  The 
water layer was washed with benzene, and then adjusted to pH 10 with 40% NaOH.  The 
water layer was then extracted with benzene, and the benzene layers washed with sat. 
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NaCl, dried over Na2SO4, and concentrated to yield Z-NH-(CH2)4-NH2 (1.392 g, 21% 
yield). 
Boc-NH-N=CH-CH(CH3)2.  To a solution of t-butyl carbazate (5.00 g, 37.9 
mmol) in EtOH (100 mL) was added isobutyraldehyde (3.00 g, 41.7 mmol), and the 
reaction was heated to reflux for 3 hrs.  The reaction was concentrated and the residue 
crystallized in water (50 mL).  The solid was filtered and dried in vacuo to yield Boc-
NH-N=CH-CH(CH3)2 (6.74 g, 95% yield). 
Boc-NH-NH-CH2CH(CH3)2.  Boc-NH-N=CH-CH(CH3)2 (5.69 g, 30.59 mmol) 
was dissolved in dry THF (80 mL) along with NaBH3CN (1.921 g, 30.59 mmol).  A 
solution of p-TsOH in THF (5.819 g, 30.59 mmol in 30 mL) was added to the mixture 
dropwise over 40 min, and the reaction was allowed to stir for 3 hrs.  The reaction was 
concentrated, and the residue taken up in EtOAc and washed with sat. NaHCO3, sat. 
NaCl, and dried over Na2SO4.  The EtOAc layer was concentrated to yield a white solid.  
The solid was taken up in 1 N NaOH (90 mL) and stirred for 1 hr.  The solution was 
neutralized with 3N HCl and extracted with CH2Cl2.  The CH2Cl2 layers were washed 
with sat. NaCl, dried over Na2SO4, and concentrated.  The crude product was purified by 
column chromatography (1:4 EtOAc:CH2Cl2) to yield Boc-NH-NH-CH2CH(CH3)2 (3.57 
g, 62% yield).  1H NMR (CDCl3): 0.91-0.94 (d, 6H), 1.42-1.48 (s, 9H), 1.69-1.76 (p, 1H), 
2.63-2.67 (d, 2H), 3.85-3.94 (s, 1H), 6.15-6.20 (s, 1H). 
Boc-ALeu-NH-(CH2)4-NH-Z.  Carbonyldiimidazole (0.517 g, 3.19 mmol) was 
dissolved in CH2Cl2 (25 mL) under argon.  A solution of Z-NH-(CH2)4-NH2 (0.75 g, 2.90 
mmol) and NMM (0.293 g, 2.90 mmol) in CH2Cl2 (10 mL) was added to the flask, and 
the reaction was allowed to stir for 45 min. A solution of Boc-NH-NH-CH2CH(CH3)2 
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(0.545 g, 2.90 mmol) and NMM (0.103 g, 1.02 mmol) in CH2Cl2 (3 mL) was added to the 
flask, and the reaction was allowed to stir overnight.  The reaction was concentrated and 
the residue was purified by column chromatography (2:1 EtOAc:Hexanes) to yield Boc-
ALeu-NH-(CH2)4-NH-Z (0.888 g, 70% yield).  1H NMR (CDCl3): 0.91-0.97 (d, 6H), 
1.44-1.49 (s, 9H), 1.52-1.67 (m, 4H), 1.70-1.78 (p, 1H), 2.64-2.70 (d, 2H), 3.15-3.26 (m, 
4H), 5.05-5.11 (s, 2H), 4.76-4.83 (s, 1H), 5.94-6.03 (s, 1H), 7.26-7.39 (m, 5H). 
ALeu-NH-(CH2)4-NH-Z·TFA.  Boc-ALeu-NH-(CH2)4-NH-Z (0.400 g, 0.917 
mmol) was dissolved in CH2Cl2 (3 mL) and cooled in an icebath.  TFA (1 mL/mmol 
reactant) was added to the flask, and the reaction was monitored by TLC until complete 
(6 hrs).  The reaction was concentrated, and the residue was crystallized in ether/hexanes 
to yield ALeu-NH-(CH2)4-NH-Z·TFA (0.297 g, 72% yield).   
EtO-(2S,3S)-EPS-ALeu-NH-(CH2)4-NH-Z.  General Mixed Anhydride 
Procedure.  (2S,3S)-Ethyl-2,3-oxirane dicarboxylate (114 mg, 0.71 mmol) was dissolved 
in CH2Cl2 (15 mL) and cooled to –20 oC in a dry ice/acetone bath.  The base NMM (72 
mg, 0.71 mmol) was added to the reaction, followed by isobutylchloroformate (97 mg, 
0.71 mmol), and the reaction was allowed to stir for 20 min. ALeu-NH-(CH2)4-NH-
Z·TFA (160 mg, 0.355 mmol) was dissolved in CH2Cl2 (2 mL) and added to the flask, 
followed by NMM (36 mg, 0.355 mmol).  The reaction was allowed to stir for 1 hr in the 
cold, then at room temperature overnight.  The reaction was concentrated, and the residue 
was purified by column chromatography (8% MeOH, 20% EtOAc, 72% CH2Cl2) to yield 
EtO-(2S,3S)-EPS-ALeu-NH-(CH2)4-NH-Z (36 mg, 21% yield).  1H NMR (CDCl3): 0.86-
1.01 (m, 9H), 1.25-1.37 (m, 4H), 1.81-2.01 (p, 1H, J = 7 Hz), 3.58-3.64 (q, 2H, J = 6 Hz), 
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3.75-3.78 (d, 1H, J = 2 Hz), 3.79-3.82 (d, 1H, J = 2 Hz), 4.21-4.33 (m, 6H), 4.66-4.72 (s, 
2H), 7.21-7.39 (m, 5H), 8.20-8.23 (s, 1H).  
(2S,3S)-3-(N2-(4-(Benzyloxycarbamoyl)butylcarbamoyl)-N1-(3-
methylbutyl)hydrazinocarbonyl)oxirane-2-carboxylic acid.  (HO-(2S,3S)-EPS-
ALeu-NH-(CH2)4-NH-Z).  EtO-(2S,3S)-EPS-ALeu-NH-(CH2)4-NH-Z (49 mg, 0.102 
mmol) was dissolved in EtOH (4 mL) and cooled in an ice bath.  A solution of 1 N NaOH 
(175 µL) was added to the flask, and the reaction allowed to stir for 1 hr in the cold, then 
for 5 hrs at room temperature.  The reaction was quenched with acetic acid and 
concentrated.  The residue was dissolved in H2O (20 mL) and washed with EtOAc.  The 
water layer was cooled in an ice bath and the pH was adjusted to 3 with 3 N HCl.  The 
water layer was extracted with EtOAc, and the organic layers were dried over Na2SO4 
and concentrated.  The residue was recrystallized from EtOAc/hexanes to yield HO-
(2S,3S)-EPS-ALeu-NH-(CH2)4-NH-Z (12 mg, 26% yield).  1H NMR (d6-DMSO): 0.78-
0.85 (d, 6H, J = 6 Hz), 1.32-1.40 (m, 4H), 1.61-1.69 (p, 1H, J = 3 Hz), 2.93-3.02 (m, 4H), 
3.13-3.18 (d, 2H, J = 5 Hz), 4.95-4.98 (s, 1H), 6.90-6.94 (s, 1H), 7.18-7.27 (m, 5H).  
HRMS (FAB): Calcd for C21H31N4O7: 451.21927.  Observed m/z: 451.22404. 
EtO-(2R,3R)-EPS-ALeu-NH-(CH2)4-NH-Z. (2R,3R)-Ethyl-2,3-oxirane 
dicarboxylate (160 mg, 0.999 mmol) and ALeu-NH-(CH2)4-NH-Z·TFA (150 mg, 0.333 
mmol) were coupled following the general mixed anhydride procedure.  The crude 
product was purified by column chromatography (8% MeOH, 20% EtOAc, 72% CH2Cl2) 
to yield EtO-(2R,3R)-EPS-ALeu-NH-(CH2)4-NH-Z (57 mg, 36% yield).  1H NMR 
(CDCl3): 0.90-0.94 (d, 6H, J = 5 Hz), 1.50-1.57 (m, 4H), 1.78-1.85 (p, 1H, J = 5 Hz), 
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3.14-3.23 (m, 4H), 3.26-3.32 (d, 2H, J = 4 Hz), 3.38-3.42 (d, 2H, J = 4 Hz), 4.89-4.96 (s, 
1H), 5.04-5.10 (s, 2H), 5.33-5.37 (s, 1H), 7.25-7.37 (m, 5H), 9.04-9.10 (s, 1H). 
(2R,3R)-3-(N2-(4-(Benzyloxycarbamoyl)butylcarbamoyl)-N1-(3-
methylbutyl)hydrazinocarbonyl)oxirane-2-carboxylic acid.  (HO-(2R,3R)-EPS-
ALeu-NH-(CH2)4-NH-Z).  EtO-(2R,3R)-EPS-ALeu-NH-(CH2)4-NH-Z (49 mg, 0.102 
mmol) was hydrolyzed with 1 N NaOH (200 µL) following the same procedure as HO-
(2S,3S)-EPS-ALeu-NH-(CH2)4-NH-Z.  The crude product was recrystallized from 
ether/hexanes to yield HO-(2R,3R)-EPS-ALeu-NH-(CH2)4-NH-Z (21 mg, 45% yield). 1H 
NMR (d6-DMSO): 0.78-0.85 (d, 6H, J = 6 Hz), 1.32-1.40 (m, 4H), 1.61-1.69 (p, 1H, J = 
5 Hz), 2.93-3.02 (m, 4H), 3.13-3.18 (d, 2H, J = 5 Hz), 4.95-4.98 (s, 1H), 6.90-6.94 (s, 
1H), 7.18-7.27 (m, 5H). HRMS (ESI): Calcd for C21H31N4O7: 451.21927.  Observed m/z: 
451.2231. 
Boc-Leu-NH-(CH2)4-NH-Z.  Boc-Leu-OH·H2O (1.125 g, 4.5 mmol) was taken 
up in toluene and evaporated several times to remove the water.  Boc-Leu-OH was 
coupled with NH2-(CH2)4-NH-Z·HCl (1.163 g, 4.5 mmol) following the general mixed 
anhydride reaction.  The crude product was purified by column chromatography (10% 
MeOH in CH2Cl2) to yield Boc-Leu-NH-(CH2)4-NH-Z (1.675 g, 85% yield).  1H NMR 
(CDCl3): 0.86-0.97 (dd, 6H), 1.38-1.45 (s, 9H), 1.48-1.55 (m, 4H), 1.65-1.71 (p, 1H), 
3.10-3.32 (m, 4H), 3.95-4.10 (m, 1H), 4.79-4.96 (s, 1H), 5.05-5.13 (s, 2H), 6.18-6.30 (s, 
1H), 7.23-7.40 (m, 5H). 
Leu-NH-(CH2)4-NH-Z·HCl.   Boc-Leu-NH-(CH2)4-NH-Z (1.675 g, 3.82 mmol) 
was dissolved in 4 N HCl/EtOAc in an ice bath and allowed to stir for 3 hrs.  The reaction 
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was concentrated in vacuo and crystallized in ether/hexanes to yield Leu-NH-(CH2)4-NH-
Z·HCl quantitatively.  
EtO-(2S,3S)-EPS-Leu-NH(CH2)4NH-Z.  (2S,3S)-Ethyl-2,3-oxirane 
dicarboxylate (212 mg, 1.20 mmol) and Leu-NH-(CH2)4-NH-Z·HCl (446 mg, 1.20 mmol) 
were coupled following the general mixed anhydride procedure.  The crude product was 
purified by recrystallization in 1:3 EtOAc:hexanes to yield EtO-(2S,3S)-EPS-Leu-
NH(CH2)4NH-Z (289 mg, 51% yield).  1H NMR (CDCl3): 0.86-0.95 (m, 9H), 1.22-1.34 
(m, 4H), 1.46-1.57 (m, 2H), 1.58-1.67 (p, 1H, J  = 5 Hz), 3.16-3.30 (m, 4H), 3.43-3.46 (d, 
1H, J = 2 Hz), 3.66-3.70 (d, 1H, J = 2 Hz), 4.22-4.30 (q, 2H, J = 3 Hz), 4.32-4.41 (m, 
1H), 4.84-4.93 (s, 1H), 5.07-5.11 (s, 2H), 6.23-6.35 (s, 1H), 6.51-6.60 (d, 1H, J = 8 Hz), 
7.25-7.38 (m, 5H).  HRMS (FAB): Calcd for C24H36N3O7: 478.25533.  Observed m/z: 
478.25560. 
(2S,3S)-3-(1-(4-Benzyloxycarbonylaminobutylcarbamoyl)-3-
methylbutylcarbamoyl)oxirane-2-carboxylic acid.  (HO-(2S,3S)-EPS-Leu-
NH(CH2)4NH-Z).  EtO-(2S,3S)-EPS-Leu-NH(CH2)4NH-Z (66 mg, 0.138 mmol) was 
hydrolyzed with 1 N NaOH (151 µL) following the same procedure as HO-(2S,3S)-EPS-
ALeu-NH-(CH2)4-NH-Z.  The crude product was recrystallized in EtOAc/hexanes to 
yield HO-(2S,3S)-EPS-Leu-NH(CH2)4NH-Z (41 mg, 66% yield).  1H NMR (d6-DMSO): 
0.78-0.89 (m, 6H), 1.20-1.28 (m, 4H), 1.32-1.38 (m, 2H), 1.39-1.48 (p, 1H, J = 3 Hz), 
2.23-2.26 (m, 1H), 2.68-2.73 (m, 1H), 2.88-3.06 (m, 4H), 4.20-4.31 (m, 1H), 4.92-4.96 
(s, 2H), 7.23-7.28 (m, 5H), 8.00-8.09 (s, 1H).  HRMS (FAB): Calcd for C22H32N3O7: 
450.22403.  Observed m/z: 450.22510. 
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N-Boc-1,4-diaminobutane (Boc-NH-(CH2)4-NH2).  To a solution of 
diaminobutane (6 g, 68.3 mmol) in dioxane (30 mL) was added BOC-ON (2-(tert-
butoxycarbonyloxyimino)-2-phenylacetonitrile) (1.923 g, 8.62 mmol) in dioxane (30 mL) 
over 2.5 hours.  The reaction was stirred overnight, during which time a white precipitate 
formed.  The dioxane was evaporated under reduced pressure, the residue was taken up in 
water (50 mL), and the solid bis-Boc-diaminobutane side product was removed by 
filtration.  The water layer was extracted with CH2Cl2 (3 × 50 mL) and the combined 
CH2Cl2 layers were dried over Na2SO4 and concentrated to give N-Boc-1,4-
diaminobutane, a clear oil, in quantitative yield.  1H NMR (CDCl3): 1.38-1.58 (m, 13H), 
2.68-2.72 (t, 2H), 3.09-3.15 (d, 2H), 3.70 (s, 2H), 4.70 (s, 1H). 
Boc-NH-(CH2)4-NH-CO-NH-CH2C6H5.  To a cooled solution of N-Boc-1,4-
diaminobutane (400 mg, 2.13 mmol) in CH2Cl2 (7 mL) was added benzyl isocyanate (283 
mg, 2.13 mmol) along with NMM (50 mg, 0.49 mmol).  The reaction was allowed to stir 
at room temperature overnight, during which time a white precipitate formed.  The 
solvent was evaporated in vacuo and the residue was purified by column chromatography 
to yield Boc-NH-(CH2)4-NH-CO-NH-CH2C6H5 (496 mg,1.42 mmol, 67%)   1H NMR 
(CDCl3): 1.41 (s, 9H), 1.50-1.56 (m, 4H), 3.08-3.16 (m, 2H), 3.20-3.24 (m, 2H), 4.38-
4.40 (d, 2H), 4.60 (s, 1H), 4.75 (s, 1H), 7.23-7.32 (m, 5H). 
NH2(CH2)4-NH-CO-NH-CH2C6H5·TFA.  To a cooled solution of Boc-NH-
(CH2)4-NH-CO-NH-CH2C6H5 (496 mg, 1.55 mmol) in CH2Cl2 (5 mL) was added TFA 
(1.5 mL) and the reaction was stirred for 2 hours on ice until reacted by TLC.  The 
solvents were evaporated in vacuo and the residue was crystallized from ether/hexanes to 
yield NH2(CH2)4-NH-CO-NH-CH2C6H5 ·TFA (505 mg, 1.50 mmol, 97% yield). 
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Boc-Leu-NH-(CH2)4-NH CO-NH-CH2C6H5.  Boc-Leu-OH H2O (378 mg, 1.51 
mmol) and NH2(CH2)4-NH-CO-NH-CH2C6H5·TFA (505 mg, 1.51 mmol) were reacting 
following the general mixed anhydride coupling procedure to yield Boc-Leu-NH-(CH2)4-
NH-CO-NH-CH2C6H5 (510 mg, 1.17 mmol, 78%). 1H NMR (CDCl3): 0.89-0.93 (t, 6H), 
1.40-1.53 (m, 15H), 1.58-1.67 (m, 1H), 3.07-3.29 (m, 4H), 4.06-4.12 (m, 1H), 4.32-4.36 
(d, 2H), 5.05-5.08 (d, 1H), 5.16-5.21 (m, 1H), 5.45 (s, 1H), 6.73 (s, 1H), 7.19-7.38 (m, 
5H). 
Leu-NH-(CH2)4-NH-CO-NH-CH2C6H5 HCl.  Leu-NH-(CH2)4-NH-CO-NH-
CH2C6H5 HCl was synthesized from Boc-Leu-NH-(CH2)4-NH CO-NH-CH2C6H5 (510 
mg, 1.17 mmol) by the same method as Leu-NH-(CH2)4-NH-Z·HCl.  The crude product 
was crystallized from ether/hexanes to yield Leu-NH-(CH2)4-NH-CO-NH-CH2C6H5 HCl 
quantitatively. 
EtO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-NH-CH2C6H5. (2S,3S)-Ethyl-2,3-
oxirane dicarboxylate (187 mg, 1.17 mmol) and Leu-NH-(CH2)4-NH-CO-NH-
CH2C6H5 HCl (433 mg, 1.17 mmol) were coupled following the general mixed anhydride 
coupling procedure. The crude product was purified by column chromatography (8% 
MeOH, 20% EtOAc, 72% CH2Cl2) to yield EtO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-
NH-CH2C6H5 (157 mg, 0.33 mmol, 28% yield). 1H NMR (CDCl3): 0.90-0.95 (t, 6H), 
1.30-1.34 (t, 3H), 1.47-1.55 (m, 4H), 1.58-1.63 (m, 1H), 1.66 (s, 2H), 3.16-3.22 (m, 4H), 
3.45-3.46 (d, 1H), 3.65-3.66 (d, 1H), 4.22-4.30 (m, 2H), 4.34-4.42 (m, 3H), 4.82 (s, 1H), 
5.06 (s, 1H), 6.64-6.72 (m, 1H), 7.20-7.33 (m, 5H). 
(2S,3S)-3-(1-(4-(3-Benzylureido)butylcarbamoyl)-3-




CH2C6H5 (137 mg, 0.29 mmol) was hydrolyzed following the same procedure as HO-
(2S,3S)-EPS-ALeu-NH-(CH2)4-NH-Z to yield HO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-
NH-CH2C6H5 (73 mg, 0.16 mmol, 57% yield). 1H NMR (d6-DMSO): 0.82-0.90 (dd, 6H, 
J = 3, 8 Hz), 1.32-1.39 (m, 4H), 1.42-1.47 (m, 2H), 1.49-1.57 (m, 1H), 2.96-3.07 (m, 
4H), 3.44-3.45 (d, 1H, J = 3 Hz), 3.64-3.65 (d, 1H, J = 3 Hz), 4.15-4.19 (d, 2H, J = 5 Hz), 
4.26-4.32 (m, 1H), 5.87-5.92 (t, 1H, J = 6 Hz), 6.22-6.27 (t, 1H, J = 6 Hz), 7.16-7.30 (m, 
5H), 8.06-8.09 (t, 1H, J = 5 Hz), 8.54-8.57 (d, 1H, J = 6 Hz).  HRMS (ESI) Calcd. for 
C22H33N4O6: 449.24001.  Observed m/z 449.2394. 
Boc-NH-(CH2)4-NH-CO-NH-C6H5.  Boc-NH-(CH2)4-NH2 (400 mg, 2.13 mmol) 
and phenyl isocyanate (253 mg, 2.13 mmol) were reacted following the same procedure 
as Boc-NH-(CH2)4-NH-CO-NH-CH2C6H5 to yield Boc-NH-(CH2)4-NH-CO-NH-C6H5 
(466 mg, 1.51 mmol, 71% yield).  1H NMR (CDCl3): 1.41-1.47 (s, 9H), 1.49-1.56 (m, 
4H), 3.10-3.18 (m, 2H), 3.23-3.30 (m, 2H), 4.62-4.69 (s, 1H), 5.13-5.23 (s, 1H), 6.60-
6.68 (s, 1H), 7.28-7.39 (m, 5H). 
NH2-(CH2)4-NH-CO-NH-C6H5 TFA.  Boc-NH-(CH2)4-NH-CO-NH-C6H5 (466 
mg, 1.52 mmol) was deblocked following the same procedure as NH2-(CH2)4-NH-CO-
NH-CH2C6H5·TFA to yield NH2-(CH2)4-NH-CO-NH-C6H5 TFA quantitatively. 
Boc-Leu-NH-(CH2)4-NH-CO-NH-C6H5.  Boc-Leu-OH H2O (380 mg, 1.52 
mmol) and NH2-(CH2)4-NH-CO-NH-C6H5 TFA (488 mg, 1.52 mmol) were coupled 
following the general mixed anhydride coupling procedure to yield Boc-Leu-NH-(CH2)4-
NH-CO-NH-C6H5 (370 mg, 0.88 mmol, 58% yield).  1H NMR (CDCl3): 0.91-0.97 (dd, 
6H), 1.41-1.45 (s, 9H), 1.47-1.56 (m, 4H), 1.58-1.62 (m, 2H), 1.65-1.71 (p, 1H), 3.12-
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3.40 (m, 4H), 4.05-4.14 (m, 1H), 4.93-5.02 (s, 1H), 5.27-5.32 (s, 1H), 6.52-6.58 (s, 1H), 
6.98-7.06 (t, 2H), 7.26-7.30 (d, 1H), 7.33-7.39 (d, 2H). 
Leu-NH-(CH2)4-NH-CO-NH-C6H5 TFA.  Boc-Leu-NH-(CH2)4-NH-CO-NH-
C6H5 (370 mg, 0.88 mmol) was deblocked following the same procedure as NH2-(CH2)4-
NH-CO-NH-CH2C6H5·TFA to yield Leu-NH2-(CH2)4-NH-CO-NH-C6H5 TFA 
quantitatively. 
EtO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-NH-C6H5.  (2S,3S)-Ethyl-2,3-
oxirane dicarboxylate (141 mg, 0.88 mmol) and Leu-NH2-(CH2)4-NH-CO-NH-C6H5 TFA 
(382 mg, 0.88 mmol) were coupled following the general mixed anhydride coupling 
procedure. The crude product was purified by column chromatography (8% MeOH, 20% 
EtOAc, 72% CH2Cl2) to yield EtO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-NH-C6H5 (61 
mg, 0.132 mmol, 15% yield).  1H NMR (d6-DMSO): 0.78-0.90 (dd, 6H), 1.34-1.42 (m, 
7H), 1.44-1.48 (m, 2H), 1.48-1.56 (p, 1H), 2.97-3.07 (m, 4H), 3.43-3.45 (d, 1H), 3.62-
3.65 (d, 1H), 4.15-4.22 (m, 2H), 4.24-4.33 (m, 1H), 6.05-6.10 (t, 1H), 6.82-6.88 (t, 1H), 
7.14-7.21 (t, 2H), 7.31-7.36 (d, 2H), 8.06-8.11 (t, 1H), 8.32-8.36 (s, 1H), 8.54-8.58 (d, 
1H). 
(2S,3S)-3-(1-(4-(3-Phenylureido)butylcarbamoyl)-3-
methylbutylcarbamoyl)oxirane-2-carboxylic acid.  (HO-(2S,3S)-EPS-Leu-NH-
(CH2)4-NH-CO-NH-C6H5).  EtO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-NH-C6H5 (61 
mg, 0.132 mmol) was deblocked following the same procedure as HO-(2S,3S)-EPS-
ALeu-NH-(CH2)4-NH-Z to yield HO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-NH-C6H5 
(36 mg, 0.83 mmol, 63% yield).  1H NMR (d6-DMSO): 0.79-0.88 (dd, 6H, J = 5, 8 Hz), 
1.34-1.40 (m, 4H), 1.41-1.46 (m, 2H), 1.48-1.56 (p, 1H, J = 5 Hz), 2.97-3.07 (m, 4H), 
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3.43-3.45 (d, 1H, J = 2 Hz), 3.62-3.65 (d, 1H, J = 2 Hz), 4.24-4.33 (m, 1H), 6.05-6.10 (t, 
1H, J = 5 Hz), 6.82-6.88 (t, 1H, J = 6 Hz), 7.14-7.21 (t, 2H, J = 6 Hz), 7.31-7.36 (d, 2H, J 
= 7 Hz), 8.06-8.11 (t, 1H, J = 4 Hz), 8.32-8.36 (s, 1H), 8.54-8.58 (d, 1H, J = 6 Hz).  
HRMS (ESI) Calcd. for C21H31N4O6: 435.223812.  Observed m/z 435.2303. 
Boc-NH-(CH2)4-NH-CO-NH-C6H4-4-(OCH3).  Boc-NH-(CH2)4-NH-Z (400 mg, 
2.13 mmol) and 4-methoxyphenyl isocyanate (317 mg, 2.13 mmol) were reacted 
following the same procedure as Boc-NH-(CH2)4-NH-CO-NH-CH2C6H5 to yield Boc-
NH-(CH2)4-NH-CO-NH-C6H4-4-(OCH3) (556 mg, 1.65 mmol, 77% yield). 1H NMR 
(CDCl3): 1.44 (s, 9H), 1.47-1.52 (m, 4H), 3.08-3.15 (d, 2H), 3.19-3.25 (s, 3H), 4.66 (s, 
1H), 5.00 (s, 1H), 6.51 (s, 1H), 6.82-6.86 (d, 2H), 7.17-7.21 (d, 2H). 
NH2-(CH2)4-NH-CO-NH-C6H4-4-(OCH3) TFA.  Boc-NH-(CH2)4-NH-CO-NH-
C6H4-4-(OCH3) (556 mg, 1.65 mmol) was deblocked following the same procedure as 
NH2(CH2)4-NH-CO-NH-CH2C6H5 ·TFA to yield NH2-(CH2)4-NH-CO-NH-C6H4-4-
(OCH3) TFA quantitatively. 
Boc-Leu-NH-(CH2)4-NH-CO-NH-C6H4-4-(OCH3).  Boc-Leu-OH H2O (413 
mg, 1.65 mmol) and NH2-(CH2)4-NH-CO-NH-C6H4-4-(OCH3) TFA (579 mg, 1.65 
mmol) were coupled following the general mixed anhydride coupling procedure to yield 
Boc-Leu-NH-(CH2)4-NH-CO-NH-C6H4-4-(OCH3) (576 mg, 1.28 mmol, 77% yield). 1H 
NMR (CDCl3): 0.92-0.96 (m, 6H), 1.43 (s, 9H), 1.48-1.50 (m, 4H), 1.61-1.71 (m, 3H), 
3.15-3.38 (m, 4H), 3.79 (s, 3H), 4.06-4.13 (m, 1H), 4.98 (s, 1H), 5.05 (s, 1H), 6.55 (s, 
1H), 6.67 (s, 1H), 6.76-6.80 (d, 2H), 7.20-7.24 (d, 2H). 
Leu-NH-(CH2)4-NH-CO-NH-C6H4-4-(OCH3) HCl.  Boc-Leu-NH-(CH2)4-NH-
CO-NH-C6H4-4-(OCH3) (576 mg, 1.28 mmol) was deblocked following the same method 
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as Leu-NH-(CH2)4-NH-Z·HCl.  The crude product was crystallized from ether/hexanes to 
yield Leu-NH-(CH2)4-NH-CO-NH-C6H4-4-(OCH3) HCl quantitatively. 
EtO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-NH-C6H4-4-(OCH3).  (2S,3S)-
Ethyl-2,3-oxirane dicarboxylate (205 mg, 1.28 mmol) and Leu-NH-(CH2)4-NH-CO-NH-
C6H4-4-(OCH3) HCl (495 mg, 1.28 mmol) were coupled following the general mixed 
anhydride coupling procedure. The crude product was purified by column 
chromatography (8% MeOH, 20% EtOAc, 72% CH2Cl2) to yield EtO-(2S,3S)-EPS-Leu-
NH-(CH2)4-NH-CO-NH-C6H4-4-(OCH3) (106 mg, 0.22 mmol, 17% yield). 1H NMR 
(CDCl3):  0.92-0.95 (t, 6H), 1.31-1.34 (t, 3H), 1.51-1.61 (m, 6H), 1.63-1.69 (m, 1H), 
3.21-3.37 (m, 4H), 3.46-3.47 (d, 1H), 3.69-3.70 (d, 1H), 3.80 (s, 3H), 4.22-4.30 (m, 2H), 
4.39-4.44 (m, 1H), 4.81-4.85 (t, 1H), 6.32 (s, 1H), 6.65-6.68 (d, 1H), 6.85-6.88 (d, 2H), 
7.18-7.21 (d, 2H).  
(2S,3S)-3-(1-(4-(3-(4-methoxyphenyl)ureido)butylcarbamoyl)-3-
methylbutylcarbamoyl)oxirane-2-carboxylic acid.  (HO-(2S,3S)-EPS-Leu-NH-
(CH2)4-NH-CO-NH-C6H4-4-(OCH3)).  EtO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-NH-
C6H4-4-(OCH3) (84 mg, 0.17 mmol) was hydrolyzed following the same procedure as 
HO-(2S,3S)-EPS-ALeu-NH-(CH2)4-NH-Z to yield HO-(2S,3S)-EPS-Leu-NH-(CH2)4-
NH-CO-NH-C6H4-4-(OCH3) (76 mg, 0.16 mmol, 96% yield). 1H NMR (d6-DMSO): 
0.82-0.88 (dd, 6H, J = 5, 9 Hz), 1.36-1.41 (m, 4H), 1.43-1.48 (m, 2H), 1.50-1.57 (m, 1H), 
3.00-3.07 (m, 4H), 3.44-3.45 (d, 1H, J = 2 Hz), 3.64-3.65 (d, 1H, J = 2 Hz), 3.67 (s, 3H), 
4.26-4.32 (m, 1H), 5.98 (s, 1H), 6.76-6.79 (d, 2H, J = 6 Hz), 7.23-7.26 (d, 2H, J = 6 Hz), 
8.08 (s, 1H), 8.14 (s, 1H), 8.54-8.56 (s, 1H).  HRMS (ESI) Calcd. for C22H33N4O7: 
465.234925.  Observed m/z 465.2269. 
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Boc-NH-(CH2)4-NH-CO-(3-pyridyl).  Boc-NH-(CH2)4-NH2 (400 mg, 2.13 
mmol) and isonicotinic acid (262 mg, 2.13 mmol) were coupled following the general 
mixed anhydride coupling procedure.  The crude product was purified by column 
chromatography (8% MeOH, 20% EtOAc, 72% CH2Cl2) to yield Boc-NH-(CH2)4-NH-
CO-(3-pyridyl) (210 mg, 0.716 mmol, 33% yield). 1H NMR (CDCl3): 1.42-1.47 (s, 9H), 
1.59-1.71 (m, 4H), 3.13-3.22 (q, 2H), 3.48-3.56 (q, 2H), 4.63-4.70 (s, 1H), 6.92-6.99 (s, 
1H), ), 7.33-7.43 (m, 1H), 8.16-8.25 (d of d, 1H), 8.61-8.74 (m, 1H).  
NH2-(CH2)4-NH-CO-(3-pyridyl) HCl.  Boc-NH-(CH2)4-NH-CO-(3-pyridyl) 
(210 mg, 0.716 mmol) was deblocked by the same method as Leu-NH-(CH2)4-NH-
Z·HCl.  The crude product was crystallized from ether/hexanes to yield NH2-(CH2)4-NH-
CO-(3-pyridyl) HCl quantitatively. 
Boc-Leu-NH-(CH2)4-NH-CO-(3-pyridyl).  Boc-Leu-OH H2O (195 mg, 0.78 
mmol) and NH2-(CH2)4-NH-CO-(3-pyridyl) HCl (178 mg, 0.78 mmol) were coupled 
following the general mixed anhydride coupling procedure to yield Boc-Leu-NH-(CH2)4-
NH-CO-(3-pyridyl) (200 mg, 0.49 mmol, 63% yield).  1H NMR (CDCl3): 0.89-0.98 (dd, 
6H), 1.40-1.45 (s, 9H), 1.57-1.76 (m, 7H), 3.21-3.39 (m, 2H), 3.45-3.56 (m, 2H), 4.05-
4.12 (m, 1H), 4.86-4.96 (s, 1H), 6.45-6.55 (s, 1H), 7.02-7.10 (s, 1H), 7.33-7.40 (m, 1H), 
8.15-8.23 (d of d, 1H), 8.66-8.72 (m, 1H), 9.09-9.15 (s, 1H). 
Leu-NH-(CH2)4-NH-CO-(3-pyridyl) TFA.  Boc-Leu-NH2-(CH2)4-NH-CO-(3-
pyridyl) (261 mg, 0.643 mmol) was deblocked following the same procedure as NH2-





oxirane dicarboxylate (103 mg, 0.643 mmol) and Leu-NH-(CH2)4-NH-CO-(3-
pyridyl) TFA (270 mg, 0.643 mmol) were coupled following the general mixed 
anhydride coupling procedure. The crude product was purified by column 
chromatography (8% MeOH, 20% EtOAc, 72% CH2Cl2) to yield EtO-(2S,3S)-EPS-Leu-
NH-(CH2)4-NH-CO-(3-pyridyl) (86 mg, 0.19 mmol, 30% yield).  1H NMR (CDCl3): 
0.87-0.95 (dd, 6H), 1.14-1.17 (t, 3H), 1.47-1.60 (m, 7H), 3.27-3.41 (m, 2H), 3.46-3.47 (d, 
1H), 3.49-3.55 (q, 2H), 3.67-3.68 (d, 1H), 4.21-4.31 (m, 2H), 4.36-4.42 (m, 1H), 6.42-
6.50 (s, 1H), 6.57-6.63 (s, 1H), 6.79-6.85 (s, 1H), 7.37-7.41 (d of d, 1H), 8.14-8.19 (d of 
t, 1H), 8.69-8.73 (d of d, 1H), 9.02-9.04 (d, 1H). 
(2S,3S)-3-(1-(4-(3-pyridylcarbamoyl)butylcarbamoyl)-3-
methylbutylcarbamoyl)oxirane-2-carboxylic acid.  (HO-(2S,3S)-EPS-Leu-NH-
(CH2)4-NH-CO-(3-pyridyl)).  EtO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-(3-pyridyl) (71 
mg, 0.158 mmol) was hydrolyzed following the same procedure as HO-(2S,3S)-EPS-
ALeu-NH-(CH2)4-NH-Z to yield HO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-(3-pyridyl) 
(12 mg , 0.029 mmol, 18% yield).  1H NMR (d6-DMSO): 0.77-0.88 (dd, 6H, J = 5, 9 Hz), 
1.37-1.58 (m, 7H), 2.97-3.10 (m, 4H), 3.42-3.45 (d, 1H, J = 2 Hz), 3.62-3.65 (d, 1H, J = 
2 Hz), 4.24-4.30 (m, 1H), 7.45-7.50 (q, 1H, J = 5 Hz), 8.06-8.11 (m, 1H), 8.13-8.19 (dt, 
1H, J = 2, 6 Hz), 8.53-8.59 (d, 1H, J = 7 Hz), 8.62-8.65 (m, 1H), 8.66-8.70 (d, 1H, J = 5 
Hz), 8.95-8.98 (s, 1H).  HRMS (ESI): Calcd for C20H29N4O6: 421.208161.  Observed m/z: 
421.2102. 
Boc-NH-(CH2)4-NH-CO-CH2-O-(1-naphthyl).  Boc-NH-(CH2)4-NH2 (1.02 g, 
5.45 mmol) and 1-naphthoxyacetic acid (1.00 g, 4.95 mmol) were coupled following the 
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general mixed anhydride coupling procedure.  The crude product was purified by column 
chromatography (8% MeOH, 20% EtOAc, 72% CH2Cl2) to yield Boc-NH-(CH2)4-NH-
CO-CH2-O-(1-naphthyl) (1.15 g, 3.09 mmol, 62% yield). 1H NMR (CDCl3): 1.44 (s, 9H), 
1.46-1.54 (m, 2H), 1.56-1.63 (m, 2H), 3.09-3.15 (q, 2H), 3.37-3.42 (q, 2H), 4.55 (s, 1H), 
4.70 (s, 2H), 6.66 (s, 1H), 6.78-6.81 (d, 1H), 7.38-7.42 (t, 1H), 7.50-7.55 (m, 3H), 7.82-
7.86 (m, 1H), 8.18-8.22 (m, 1H). 
NH2-(CH2)4-NH-CO-CH2-O-(1-naphthyl) HCl.  Boc-NH-(CH2)4-NH-CO-CH2-
O-(1-naphthyl) (1.15 g, 3.09 mmol) was deblocked following the same procedure as Leu-
NH-(CH2)4-NH-Z·HCl.  The crude product was crystallized from ether/hexanes to yield 
NH2-(CH2)4-NH-CO-CH2-O-(1-naphthyl) HCl (841 mg, 3.04 mmol, 98% yield).  
Boc-Leu-NH-(CH2)4-NH-CO-CH2-O-(1-naphthyl).  Boc-Leu-OH H2O (760 
mg, 3.04 mmol) and NH2-(CH2)4-NH-CO-CH2-O-(1-naphthyl) HCl (841mg, 3.04 mmol) 
were coupled following the general mixed anhydride coupling procedure. The crude 
product was purified by column chromatography (8% MeOH, 20% EtOAc, 72% CH2Cl2) 
to yield Boc-Leu-NH-(CH2)4-NH-CO-CH2-O-(1-naphthyl) (288 mg, 0.59 mmol, 20% 
yield).  1H NMR (CDCl3): 0.91-0.99 (m, 6H), 1.42 (s, 9H), 1.51-1.62 (m, 7H), 3.21-3.31 
(m, 2H), 3.38-3.43 (m, 2H), 4.20 (s, 1H), 4.72 (s, 2H), 4.83 (s, 1H), 6.22 (s, 1H), 6.73 (s, 
1H), 6.79-6.83 (d, 1H), 7.38-7.42 (t, 1H), 7.49-7.56 (m, 3H), 7.82-7.87 (m, 1H), 8.18-
8.24 (m, 1H). 
Leu-NH-(CH2)4-NH-CO-CH2-O-(1-naphthyl) HCl.  Boc-Leu-NH-(CH2)4-NH-
CO-CH2-O-(1-naphthyl) (288 mg, 0.59 mmol) was deblocked by the same method as 
Leu-NH-(CH2)4-NH-Z·HCl.  The crude product was crystallized from ether/hexanes to 
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yield Leu-NH-(CH2)4-NH-CO-CH2-O-(1-naphthyl) HCl (229 mg, 0.53 mmol, 92% 
yield). 
EtO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-CH2-O-(1-naphthyl).  (2S,3S)-
Ethyl-2,3-oxirane dicarboxylate (96 mg, 0.54 mmol) and Leu-NH-(CH2)4-NH-CO-CH2-
O-(1-naphthyl) HCl (229 mg, 0.54 mmol) were coupled following the general mixed 
anhydride coupling procedure. The crude product was purified by column 
chromatography (8% MeOH, 20% EtOAc, 72% CH2Cl2) to yield EtO-(2S,3S)-EPS-Leu-
NH-(CH2)4-NH-CO-CH2-O-(1-naphthyl) (129 mg, 0.24 mmol, 45% yield).  1H NMR 
(CDCl3): 0.87-0.95 (m, 6H), 1.29-1.33 (t, 3H), 1.47-1.66 (m, 7H), 3.23-3.29 (m, 2H), 
3.37-3.40 (m, 2H), 3.42-3.43 (d, 2H), 3.66-3.67 (d, 1H), 4.20-4.29 (m, 2H), 4.31-4.37 (m, 
1H), 4.71 (s, 2H), 6.21 (s, 1H), 6.46-6.49 (d, 1H), 6.80-6.82 (d, 1H), 7.35-7.39 (t, 1H), 
7.47-7.54 (m, 3H), 7.80-7.85 (m, 1H), 8.16-8.22 (m, 1H). 
(2S,3S)-3-(1-(4-(2-(1-naphthaloxy)acetylamino)butylcarbamoyl)-3-
methylbutylcarbamoyl)oxirane-2-carboxylic acid.  (HO-(2S,3S)-EPS-Leu-NH-
(CH2)4-NH-CO-CH2-O-(1-naphthyl)).  EtO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-
CH2-O-(1-naphthyl) (115 mg, 0.22 mmol) was hydrolyzed with 1 N NaOH (294 µL) 
following the same method as HO-(2S,3S)-EPS-ALeu-NH-(CH2)4-NH-Z to yield HO-
(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-CH2-O-(1-naphthyl) (87 mg, 0.17 mmol, 80% 
yield).  1H NMR (CDCl3): 0.91-0.97 (t, 6H, J = 5 Hz), 1.48-1.69 (m, 7H), 3.19-3.33 (m, 
2H), 3.37-3.42 (q, 2H, J = 5 Hz), 3.60 (s, 2H), 4.46-4.53 (m, 1H), 4.72 (s, 2H), 6.76 (s, 
1H), 6.79-6.84 (d, 1H, J = 5 Hz), 7.37-7.41 (t, 1H, J = 6 Hz), 7.49-7.53 (m, 3H), 7.81-
7.87 (m, 1H), 8.16-8.21 (m, 1H).  HRMS (ESI) Calcd. for C26H34N3O7: 500.239676.  
Observed m/z 500.2324. 
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Boc-NH-(CH2)4-NH-CO-CH2-O-(2-naphthyl).  Boc-NH-(CH2)4-NH2 (1.02 g, 
5.45 mmol) and 2-naphthoxyacetic acid (1.00 g, 4.95 mmol) were coupled following the 
general mixed anhydride coupling procedure.  The crude product was purified by column 
chromatography (8% MeOH, 20% EtOAc, 72% CH2Cl2) to yield Boc-NH-(CH2)4-NH-
CO-CH2-O-(2-naphthyl) (1.32g, 3.54 mmol, 71% yield)  1H NMR (CDCl3): 1.45 (s, 9H), 
1.46-1.53 (m, 2H), 1.55-1.62 (m, 2H), 3.07-3.12 (q, 2H), 3.37-3.42 (q, 2H), 4.55 (s, 1H), 
4.70 (s, 2H), 6.19-6.24 (t, 1H), 6.50-6.55 (d, 1H), 6.72-6.79 (s, 1H), 7.11-7.23 (m, 1H), 
7.35-7.41 (t, 1H), 7.44-7.50 (t, 1H), 7.70-7.81 (m, 4H). 
NH2-(CH2)4-NH-CO-CH2-O-(2-naphthyl) HCl.  Boc-NH-(CH2)4-NH-CO-CH2-
O-(2-naphthyl) (1.15 g, 3.09 mmol) was deblocked following the same procedure as Leu-
NH-(CH2)4-NH-Z·HCl.  The crude product was crystallized from ether/hexanes to yield 
NH2-(CH2)4-NH-CO-CH2-O-(2-naphthyl) HCl quantitatively. 
Boc-Leu-NH-(CH2)4-NH-CO-CH2-O-(2-naphthyl).  Boc-Leu-OH H2O (768 
mg, 3.07 mmol) and NH2-(CH2)4-NH-CO-CH2-O-(2-naphthyl) HCl (850mg, 3.07 mmol) 
were coupled following the general mixed anhydride coupling procedure. The crude 
product was purified by column chromatography (8% MeOH, 20% EtOAc, 72% CH2Cl2) 
to yield Boc-Leu-NH-(CH2)4-NH-CO-CH2-O-(2-naphthyl) (328 mg, 0.67 mmol, 23% 
yield).  1H NMR (CDCl3): 0.87-0.99 (m, 6H), 1.45 (s, 9H), 1.51-1.63 (m, 7H), 3.20-3.31 
(m, 2H), 3.38-3.43 (m, 2H), 4.18 (s, 1H), 4.68 (s, 2H), 4.85 (s, 1H), 6.19-6.24 (t, 1H), 
6.50-6.55 (d, 1H), 6.72-6.79 (s, 1H), 7.13-7.24 (m, 1H), 7.35-7.41 (t, 1H), 7.44-7.50 (t, 
1H), 7.70-7.81 (m, 4H). 
Leu-NH-(CH2)4-NH-CO-CH2-O-(2-naphthyl) HCl.  Boc-Leu-NH-(CH2)4-NH-
CO-CH2-O-(2-naphthyl) (328 mg, 0.67 mmol) was deblocked by the same method as 
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Leu-NH-(CH2)4-NH-Z·HCl.  The crude product was crystallized from ether/hexanes to 
yield Leu-NH-(CH2)4-NH-CO-CH2-O-(2-naphthyl) HCl (240 mg, 0.55 mmol, 96% 
yield). 
EtO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-CH2-O-(2-naphthyl).  (2S,3S)-
Ethyl-2,3-oxirane dicarboxylate (98 mg, 0.55 mmol) and Leu-NH-(CH2)4-NH-CO-CH2-
O-(2-naphthyl) HCl (240 mg, 0.55 mmol) were coupled following the general mixed 
anhydride coupling procedure. The crude product was purified by column 
chromatography (8% MeOH, 20% EtOAc, 72% CH2Cl2) to yield EtO-(2S,3S)-EPS-Leu-
NH-(CH2)4-NH-CO-CH2-O-(2-naphthyl) (46 mg, 0.087 mmol, 16% yield).  1H NMR 
(CDCl3): 0.90-0.97 (dd, 6H), 1.29-1.33 (t, 3H), 1.48-1.70 (m, 7H), 3.21-3.30 (m, 2H), 
3.36-3.42 (m, 2H), 3.45-3.46 (d, 1H), 3.68-3.69 (d, 1H), 4.22-4.30 (q, 2H), 4.32-4.39 (m, 
1H), 4.62-4.64 (s, 2H), 6.19-6.24 (t, 1H), 6.50-6.55 (d, 1H), 6.72-6.79 (s, 1H), 7.11-7.23 
(m, 1H), 7.35-7.41 (t, 1H), 7.44-7.50 (t, 1H), 7.70-7.81 (m, 4H).  HRMS (FAB): Calcd 
for C28H38N3O7: 528.270976.  Observed m/z: 528.262. 
(2S,3S)-3-(1-(4-(2-(2-naphthaloxy)acetylamino)butylcarbamoyl)-3-
methylbutylcarbamoyl)oxirane-2-carboxylic acid.  (HO-(2S,3S)-EPS-Leu-NH-
(CH2)4-NH-CO-CH2-O-(2-naphthyl)).  EtO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-
CH2-O-(2-naphthyl) (46 mg, 0.087 mmol) was hydrolyzed with 1 N NaOH (117 µL) 
following the same method as HO-(2S,3S)-EPS-ALeu-NH-(CH2)4-NH-Z to yield HO-
(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-CH2-O-(2-naphthyl) (29 mg, 0.058 mmol, 67% 
yield).  1H NMR (d6-DMSO): 0.79-0.89 (dd, 6H, J = 5, 8 Hz), 1.32-1.48 (m, 4H), 1.48-
1.58 (m, 1H), 2.93-3.06 (m, 4H), 3.10-3.17 (m, 2H), 3.43-3.45 (d, 1H, J = 2 Hz), 3.63-
3.65 (d, 1H, J = 2 Hz), 4.25-4.32 (m, 1H), 4.53-4.56 (s, 2H), 7.20-7.27 (m, 2H), 7.31-
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7.36 (t, 1H, J = 7 Hz), 7.41-7.46 (t, 1H, J = 7 Hz), 7.73-7.77 (d, 1H, J = 6 Hz), 7.79-7.85 
(t, 2H, J = 6 Hz), 8.04-8.08 (t, 1H, J = 5 Hz), 8.11-8.16 (t, 1H, J = 5 Hz), 8.54-8.57 (d, 
1H, J = 6 Hz). HRMS (ESI) Calcd. for C26H34N3O7: 500.239127.  Observed m/z 
500.2422. 
Boc-NH-(CH2)4-NH-CO-NH-(1-naphthyl).  Boc-NH-(CH2)4-NH2 (400 mg, 2.13 
mmol) and 1-naphthyl isocyanate (360 mg, 2.13 mmol) were reacted following the same 
method as Boc-NH-(CH2)4-NH-CO-NH-CH2C5H6 to yield Boc-NH-(CH2)4-NH-CO-NH-
(1-naphthyl) (510 mg, 1.42 mmol, 67% yield). 1H NMR (CDCl3): 1.43 (s, 9H), 1.46-1.48 
(m, 4H), 3.08-3.12 (m, 2H), 3.21-3.27 (d, 2H), 4.56 (s, 1H), 4.87 (s, 1H), 6.48 (s, 1H), 
7.45-7.49 (t, 1H), 7.52-7.59 (m, 3H), 7.74-7.78 (d, 1H), 7.85-7.89 (m, 1H), 8.03-8.07 (m, 
1H). 
NH2-(CH2)4-NH-CO-NH-(1-naphthyl) TFA.  Boc-NH-(CH2)4-NH-CO-NH-(1-
naphthyl) (510 mg, 1.42 mmol) was deblocked following the same method as NH2-
(CH2)4-NH-CO-NH-CH2C5H6·TFA to yield NH2-(CH2)4-NH-CO-NH-(1-naphthyl) TFA 
quantitatively. 
Boc-Leu-NH-(CH2)4-NH CO-NH-(1-naphthyl).  Boc-Leu-OH H2O (355 mg, 
1.42 mmol) and NH2-(CH2)4-NH-CO-NH-(1-naphthyl) TFA (527 mg, 1.42 mmol) were 
coupled following the general mixed anhydride coupling procedure to yield Boc-Leu-
NH-(CH2)4-NH-CO-NH-(1-naphthyl) (419 mg, 0.891 mmol, 63% yield). 1H NMR 
(CDCl3): 0.90-0.93 (t, 6H), 1.41 (s, 9H), 1.46-1.52 (m, 4H), 1.59-1.60 (m, 3H), 3.13-3.33 
(m, 4H), 4.07-4.15 (m, 1H), 4.92-4.98 (d, 1H), 5.21 (s, 1H), 6.54-6.58 (t, 1H), 7.00 (s, 
1H), 7.43-7.51 (m, 3H), 7.67-7.70 (d, 2H), 7.83-7.88 (m, 1H), 8.04-8.08 (m, 1H). 
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Leu-NH-(CH2)4-NH-CO-NH-(1-naphthyl) HCl.  Boc-Leu-NH-(CH2)4-NH-CO-
NH-(1-naphthyl) (419 mg, 0.89 mmol) was deblocked by the same method as Leu-NH-
(CH2)4-NH-Z·HCl.  The crude product was crystallized from ether/hexanes to yield Leu-
NH-(CH2)4-NH-CO-NH-(1-naphthyl) HCl quantitatively. 
EtO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-NH-(1-naphthyl).  (2S,3S)-Ethyl-
2,3-oxirane dicarboxylate (142 mg, 0.89 mmol) and Leu-NH-(CH2)4-NH-CO-NH-(1-
naphthyl) HCl (362 mg, 0.89 mmol) were coupled following the general mixed anhydride 
coupling procedure. The crude product was purified by column chromatography (8% 
MeOH, 20% EtOAc, 72% CH2Cl2) to yield EtO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-
NH-(1-naphthyl) (92 mg, 0.18 mmol, 21% yield).  1H NMR (CDCl3): 0.87-0.99 (m, 6H), 
1.29-1.33 (t, 3H), 1.48-1.55 (m, 6H), 1.64-1.71 (p, 1H), 3.21-3.23 (m, 4H), 3.45-3.46 (d, 
1H), 3.69-3.70 (d, 1H), 4.21-4.29 (m, 2H), 4.39-4.40 (m, 1H), 4.82-4.86 (t, 1H), 6.57-
6.68 (m, 2H), 7.46-7.51 (q, 1H), 7.52-7.57 (m, 2H), 7.75-7.78 (d, 1H), 7.87-7.92 (m, 1H), 
8.03-8.07 (d, 1H). 
(2S,3S)-3-(1-(4-(3-(2-naphthyl)ureido)butylcarbamoyl)-3-
methylbutylcarbamoyl)oxirane-2-carboxylic acid.  (HO-(2S,3S)-EPS-Leu-NH-
(CH2)4-NH-CO-NH-(1-naphthyl)).  EtO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-NH-(1-
naphthyl) (92 mg, 0.18 mmol) was hydrolyzed following the same procedure as HO-
(2S,3S)-EPS-ALeu-NH-(CH2)4-NH-Z to yield HO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-
NH-(1-naphthyl) (58 mg, 0.12 mmol, 67% yield).  1H NMR (d6-DMSO): 0.82-0.88 (m, 
6H), 1.43-1.49 (m, 6H), 1.51-1.57 (m, 1H), 3.03-3.15 (m, 4H), 3.45-3.46 (d, 1H, J = 2 
Hz), 3.64-3.65 (d, 1H, J = 2 Hz), 4.27-4.34 (m, 1H), 6.58 (s, 1H), 7.38-7.42 (t, 1H, J = 6 
Hz), 7.47-7.53 (m, 2H), 7.84-7.87 (d, 1H, J = 6 Hz), 7.96-7.98 (d, 1H, J = 6 Hz), 8.02-
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8.06 (d, 1H, J = 6 Hz), 8.08-8.13 (m, 1H), 8.44 (s, 1H), 8.54-8.58 (d, 1H, J = 6 Hz).  
HRMS (ESI) Calcd. for C25H33N4O6: 485.24001.  Observed m/z 485.2388. 
Boc-NH-(CH2)4-NH-CO-NH-C6H4-2-(OC6H5).  Boc-NH-(CH2)4-NH2 (400 mg, 
2.13 mmol) and 2-phenoxyphenyl isocyanate (493 mg, 2.13 mmol) were reacted 
following the same procedure as Boc-NH-(CH2)4-NH-CO-NH-CH2C5H6 to yield Boc-
NH-(CH2)4-NH-CO-NH-C6H4-2-(OC6H5) (850 mg, 2.13 mmol, 100% yield).  1H NMR 
(CDCl3): 1.39-1.44 (s, 9H), 1.50-1.56 (m, 4H), 3.06-3.16 (m, 2H), 3.22-3.30 (m, 2H), 
4.55-4.62 (s, 1H), 5.06-5.14 (s, 1H), 6.85-6.87 (d, 2H), 6.89-6.94 (t, 1H), 6.95-7.00 (d, 
2H), 7.05-7.14 (m, 2H), 7.28-7.35 (m, 2H), 8.11-8.19 (m, 1H). 
NH2-(CH2)4-NH-CO-NH-C6H4-2-(OC6H5) TFA.  Boc-NH-(CH2)4-NH-CO-NH-
C6H4-2-(OC6H5) (850 mg, 2.13 mmol) was deblocked following the same procedure as 
NH2(CH2)4-NH-CO-NH-CH2C6H5·TFA to yield NH2-(CH2)4-NH-CO-NH-C6H4-2-
(OC6H5) TFA quantitatively. 
Boc-Leu-NH-(CH2)4-NH-CO-NH-C6H4-2-(OC6H5).  Boc-Leu-OH H2O (560 
mg, 2.24 mmol) and NH2-(CH2)4-NH-CO-NH-C6H4-2-(OC6H5) TFA (392 mg, 2.13 
mmol) were coupled following the general mixed anhydride coupling procedure to yield 
Boc-Leu-NH-(CH2)4-NH-CO-NH-C6H4-2-(OC6H5) (529 mg, 1.03 mmol, 46% yield).  1H 
NMR (CDCl3): 0.84-0.89 (dd, 6H), 1.34-1.38 (s, 9H), 1.41-1.62 (m, 7H), 2.92-3.38 (m, 
4H), 4.07-4.15 (d, 1H), 4.95-5.01 (d, 1H), 5.71-5.79 (s, 1H), 6.71-6.77 (s, 1H), 6.78-6.82 
(d, 1H), 6.85-6.90 (t, 1H), 6.96-7.09 (m, 2H), 7.27-7.33 (t, 2H), 7.44-7.49 (s, 1H), 8.26-
8.32 (d, 1H). 
Leu-NH-(CH2)4-NH-CO-NH-C6H4-2-(OC6H5) TFA.  Boc-Leu-NH-(CH2)4-NH-
CO-NH-C6H4-2-(OC6H5) (529 mg, 1.03 mmol) was deblocked following the same 
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procedure as NH2(CH2)4-NH-CO-NH-CH2C6H5·TFA to yield Leu-NH-(CH2)4-NH-CO-
NH-C6H4-2-(OC6H5) TFA (505 mg, 0.96 mmol, 93% yield). 
EtO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-NH-C6H4-2-(OC6H5).  (2S,3S)-
Ethyl-2,3-oxirane dicarboxylate (154 mg, 0.96 mmol) and Leu-NH-(CH2)4-NH-CO-NH-
C6H4-2-(OC6H5) TFA (505 mg, 0.96 mmol) were coupled following the general mixed 
anhydride coupling procedure. The crude product was purified by column 
chromatography (8% MeOH, 20% EtOAc, 72% CH2Cl2) to yield EtO-(2S,3S)-EPS-Leu-
NH2-(CH2)4-NH-CO-NH-C6H4-2-(OC6H5) (136 mg, 0.24 mmol, 26% yield).  1H NMR 
(CDCl3): 0.86-0.95 (dd, 6H), 1.28-1.33 (t, 3H), 1.45-1.66 (m, 7H), 3.10-3.37 (m, 4H), 
3.40-3.42 (d, 1H), 3.63-3.65 (d, 1H), 4.19-4.29 (q, 2H), 4.33-4.40 (m, 1H), 5.21-5.25 (t, 
1H), 6.48-6.54 (t, 1H), 6.60-6.64 (d, 1H), 6.78-6.84 (d, 1H), 6.88-6.93 (t, 1H), 6.94-6.99 
(d, 2H), 7.04-7.13 (m, 3H), 7.27-7.34 (t, 2H), 8.14-8.19 (d, 1H). 
(2S,3S)-3-(1-(4-(3-(2-phenoxyphenyl)ureido)butylcarbamoyl)-3-
methylbutylcarbamoyl)oxirane-2-carboxylic acid.  (HO-(2S,3S)-EPS-Leu-NH-
(CH2)4-NH-CO-NH-C6H4-2-(OC6H5)).  EtO-(2S,3S)-EPS-Leu-NH-(CH2)4-NH-CO-NH-
C6H4-2-(OC6H5) (125 mg, 0.225 mmol) was hydrolyzed following the same procedure as 
HO-(2S,3S)-EPS-ALeu-NH-(CH2)4-NH-Z to yield HO-(2S,3S)-EPS-Leu-NH-(CH2)4-
NH-CO-NH-C6H4-2-(OC6H5) (118 mg, 0.226 mmol, 100%).  1H NMR (d6-DMSO): 0.78-
0.88 (dd, 6H, J = 5, 9 Hz), 1.31-1.38 (m, 4H), 1.39-1.45 (m, 2H), 1.47-1.55 (p, 1H, J = 4 
Hz), 2.93-3.08 (m, 4H), 3.42-3.44 (d, 1H, J = 2 Hz), 3.61-3.64 (d, 1H, J = 2 Hz), 4.24-
4.32 (m, 1H), 6.74-6.88 (m, 3H), 6.93-6.98 (d, 1H, J = 5 Hz), 6.99-7.05 (t, 1H, J = 5 Hz), 
7.08-7.12 (t, 1H, J = 5 Hz), 7.32-7.40 (t, 2H, J = 6 Hz), 8.03-8.10 (m, 2H), 8.19-8.24 (d, 
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1H, J = 6 Hz), 8.51-8.56 (d, 1H, J = 6 Hz).  HRMS (ESI) Calcd. for C27H35N4O7: 






SOLID-PHASE SYNTHESIS OF AZA-PEPTIDE MICHAEL ACCEPTOR 






Caspases.  The term “caspase” originates from cysteinyl aspartate specific protease.  
Caspase-1, or ICE (interleukin-1β converting enzyme), was the first member of the 
caspase family identified.46  ICE is responsible for the proteolytic maturation of proIL-1β 
to its pro-inflammatory, active form.47  ICE represented a new class of cysteine proteases 
based on general structural organization and the absolute requirement for a P1 Asp 
residue.  Subsequent caspases were discovered and linked to ICE through the homology 
of ICE with the protein CED-3, which was known to be involved for cell death in C. 
elegans.48   
 There are 14 mammalian caspases identified to date, of which 11 are human 
enzymes.49  The caspases can be divided into three groups.  Group I caspases (1, 4, 5, 13) 
are mediators of inflammation, and known as cytokine activators.  Groups II and III are 
both involved in apoptosis, but differ in their role in the apoptosis cascade and general 
substrate specificity.  Group II caspases (3, 6, 7) are known as executioner caspases, and 
are effectors of cell death.  Group III caspases (2, 8, 9, 10) are initiator caspases, and are 
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upstream of Group II caspases in the apoptosis cascade.  Studies have shown that initiator 
caspase-8 is an activator of caspases -3 and -7,50 while initiator caspase-9 is an activator 
of caspase-3.51   
 Caspases exist as inactive zymogens in cells.52  Group II initiator caspases are 
activated through the extrinsic pathway, including binding of adaptor molecules through 
their N-terminal prodomain.  The adaptor molecules are recruited by ligand-mediated 
trimerization at the cell surface.  The executioner caspases are then activated through 
proteolytic cleavage of their zymogen prodomain.  Two intrinsic pathways of apoptosis 
activation exist, in which cellular stress leads to caspase-9 activation mediated by 











Caspase Specificity.  Other than the serine protease Granzyme B, the caspases are the 
only proteases that are specific for a P1 Asp residue in substrates and inhibitors.  All 
caspases display a strict and rigid requirement for a P1 Asp residue.  The caspases 
recognize a tetrapeptide sequence in protein substrates which spans the S4-S1 region of 
the active site.  The S4 subsite is the most diverse among caspases and provides for the 
most differentiation between caspases.  Group I caspases have larger, more hydrophobic 
S4 pockets and prefer a P4 Trp residue.  Group II caspases have smaller, more 
hydrophilic S4 subsites and are highly selective for a P4 Asp residue.  Group III caspases 
have a wider P4 tolerance, but prefer branched, aliphatic side chains such as Val, Leu, or 
Ile.  The S3 pocket of caspases is highly conserved, and contains a conserved Arg residue 
that has an ionic interaction with a P3 Glu, the preferred residue at this position in 
caspases.  In the S2 subsite, Group I caspases prefer a His residue, Group II caspases 
prefer small aliphatic side chains, and Group III can accommodate a larger variety of side 
chains.  The three-dimensional structure of protein substrates is also a key factor in 
determining whether the presence of the appropriate peptide sequence makes it eligible 




Table 3.1.  Sequence Specificity of Caspases. 
Group Caspase Sequence Specificity 
Group I Caspase-1 Trp-Glu-His-Asp 
Cytokine Activators Caspase-4 Trp-Glu-His-Asp 
 Caspase-5 Trp-Glu-His-Asp 
 Caspase-13 not determined 
   
Group II Caspase-3 Asp-Glu-X-Asp 
Executioner Caspases Caspase-6 Leu, Val, Ile-Glu-X-Asp 
 Caspase-7 Asp-Glu-X-Asp 
   
Group III Caspase-2 Asp-Glu-X-Asp 
Initiator Caspases Caspase-8 Val, Leu, Ile-Glu-X-Asp 
 Caspase-9 Val, Leu, Ile-Glu-X-Asp 
 Caspase-10 Val, Leu, Ile-Glu-X-Asp 




 Little is known about substrate and inhibitor specificity on the prime side of the 
caspase active site.  Crystal structures of caspases suggest that the prime side interactions 
could help to differentiate between the caspases in substrates and inhibitors. 
 
Caspase Structure.  Caspases are composed of three domains, including the large 
subunit, the small subunit, and the N-terminal prodomain.53  Both the large and small 
subunits contribute residues that form the active site binding cleft, however the major 
determinants for substrate specificity between caspases (the S4 subsite) are found in the 
small subunit.   
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The crystal structure of caspases -1,54 -3,55,56 -7,57 -8,58 and -959 have been solved 
alone and/or with inhibitors bound.  Models of the active sites of the other caspases have 
been proposed based on sequence homology with the known caspase structures.60  The 
general caspase-substrate interactions can be seen in Figure 3.2, with caspase-1 
numbering.  A Cys285 and His237 form the conserved catalytic dyad in the active site.  
Two Arg residues and a Gln residue in the S1 pocked interact with the P1 Asp side chain.  
Ser339 and Arg341 make hydrogen bonding contacts with the substrate backbone.  The 
conserved Gly238 and Cys285 backbone form an “oxyanion hole” which stabilized the 














































Caspases in Diseases.  Caspases are major players in any disease or condition that 
involves excessive levels of apoptosis.  Caspase involvement has been shown in 
myocardial infarction,61 stroke,62 traumatic brain injury,63 spinal cord injury,64 sepsis,65 
liver failure,66 Alzheimers disease,67 Parkinsons disease,68 and Huntington’s disease.69  
Group I caspases are involved in inflammatory conditions, such as rheumatoid arthritis.70  
Caspases are the main targets of drug design to stop excessive apoptosis.  Hence, caspase 
inhibitors have great therapeutic potential for a wide variety of diseases.  
 
Caspase Inhibitors.  Caspase inhibitors generally have involved a tetrapeptide sequence 
(based on substrate specificity) along with a warhead that interacts with the active site 
cysteine residue.  Several of these inhibitors have been used extensively to elucidate the 
roles of caspases in cellular systems.  These inhibitors include peptide aldehydes (Ac-
DEVD-H, Ac-YVAD-H) and peptide halomethylketones (Z-VAD-CH2F, Ac-DEVD-
CH2Cl, Ac-DEVD-CH2F, Z-IETD-CH2F, Z-LEHD-CH2F, Ac-YVAD-CH2Cl).17   
 One of the problems with these inhibitors is that they are not as specific for 
caspases as originally thought.71  For instance, many of these inhibitors contain a P2 Val 
residue, which is a preference of the clan CA enzyme calpain.  It has been demonstrated 
that these “caspase-specific” inhibitors also inhibit calpain.72  Given that calpain is also a 
major player in neurodegenerative diseases and conditions, the use of these inhibitors to 
elucidate caspase roles should be questioned. 
Another problem with these inhibitors is that they are not able to absolutely 
differentiate between caspases.  Even with their tetrapeptide specificity sequences, a 
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specific inhibitor does not exist for many of the caspases.  Inhibitors that are specific for 









Caspase-1 18 280,000 
Caspase-4 132 5500 
Caspase-5 205 130,000 
Caspase-3 0.23 16,000 
Caspase-6 31 7,100 
Caspase-7 1.6 18,000 
Caspase-2 1710 290 
Caspase-8 0.92 280,000 
Caspase-9 60 180,000 
Caspase-10 12 nd 




Caspase Inhibitors As Therapeutic Agents.  The peptidic nature of many caspase 
inhibitors gives them poor pharmacokinetic properties, therefore rendering them poor 
drug candidates.  The peptide portion of these inhibitors gives them poor membrane 
permeability as well as makes them susceptible to metabolic elimination.  One area of 
research is the development of peptidomimetics to replace the tetrapeptide portion of 







The Powers laboratory has been successful in the design of aza-peptide epoxide 
and Michael acceptor inhibitors for caspases, with rates of inhibition in the millions.43,75  
The aza-peptide epoxide and Michael acceptor design included extending the inhibitor in 
the P1’ direction in order to discover inhibitors that are selective between the caspases. 
We have been successful in utilizing the S1’ subsite as a specificity determinant.  In an 
extension of these series of inhibitors, we designed a series of aza-peptide Michael 
acceptor inhibitors that would explore the S3’ subsite and could be synthesized by solid 
phase synthetic methods. 
Aza-peptide Michael acceptor inhibitors.  The aza-peptide epoxide design was 
described previously in reference to calpain inhibitors.  The aza-peptide Michael acceptor 
design is an extension of the epoxide design, where a double bond is substituted for the 





























Similar to the aza-peptide epoxide inhibitors, the protease cysteine thiol in the 
active site attacks one of the double bond carbons in a Michael acceptor reaction.  The 
cysteine residue is alkylated by the inhibitor and the enzyme is permanently inactivated.  
Examples of a few Michael acceptor inhibitors discovered in the Powers laboratory can 




Table 3.3.  Representative Aza-Peptide Michael Acceptor Inhibitors for Caspases. 
  kobs/[I] (M-1s-1) 
No Inhibitor Caspase 3 Caspase 6 Caspase 8 
1 Z-DEVaD-CH=CH-COOEt 2,130,000 35,600 273,000 
2 Z-DEVaD-CH=CH-CON(CH3)Bzl 2,640,000 9,500 90,300 
3 Z-LETaD-CH=CH-COOEt 5,560 18,700 237,000 





New Aza-Peptide Michael Acceptor inhibitors: Scanning the P3’ Subsites of 
Caspases.  The new aza-peptide Michael acceptor inhibitor design serves two purposes.  
The first objective is to develop solid phase synthesis methods to speed the synthesis and 
increase the yields of aza-peptide Michael acceptors.  The second objective is to explore 
the specificity of the P3’ region of caspases, which has so far not been investigated. 
The solution phase synthesis of aza-peptide epoxide and Michael acceptor 
inhibitors is slow and tedious, involving many peptide bond formation steps.  Purification 
of the inhibitors is difficult and final inhibitor yields are low.  Given the many peptide 
bonds in these caspase inhibitors, they are good candidates for solid phase peptide 
synthetic methods.  Using the Wang resin and standard Fmoc amino acid coupling 
procedures, these inhibitors could be synthesized easily from the C-terminal end.  In 
order to incorporate the aza-peptide Michael acceptor moiety into solid phase synthesis, a 
Fmoc unit containing the inhibitor warhead must be designed and synthesized.  The unit 
chosen can be seen in Figure 3.4.  Fmoc-AAsp(O-tBu)CH=CH-COOH combines the 
AAsp residue and the double bond warhead, and can be easily synthesized in three steps.  
For ease of synthesis, we chose to investigate Michael acceptor inhibitors first, however 




















We chose three tetrapeptide sequences for the non-prime side of the Michael 
acceptors based on preferred substrate sequences.  The Z-Asp-Glu-Val-AAsp sequence 
was chosen for caspases-3 and -7.  The sequence Z-Leu-Glu-Thr-AAsp was chosen for 
caspase-8.  The sequence Z-Ile-Glu-Thr-AAsp was chosen for caspase-6.   
Five representative amino acids were chosen for the P3’ position of the inhibitors.  
Ala was chosen as a small aliphatic residue, Phe was chosen as an aromatic, Leu was 
chosen as a hydrophobic aliphatic residue, Glu was chosen for its negatively charged side 
chain, and Lys was chosen for its positively charged side chain.  A Gly residue was 
placed in the P2’ position as a spacer between the double bond and the P3’ residues.  
Combining the 3 tetrapeptide sequences with the five P3’ residue gives a library of 15 






















The synthesis of the Fmoc-AAsp(O-tbu)-CH=CH-COOH unit can be seen in 
Figure 3.6.  Fmoc chloroformate is treated with hydrazine to yield Fmoc-hydrazine 6, 
which is reacted with t-butylbromoacetate to incorporate the blocked Asp side chain (7).  
The hydrazide is then coupled by the mixed anhydride method with fumaric acid, which 
is present in excess to prevent bis coupling.  This unit is now ready to be incorporated 




































Figure 3.6.  Synthesis of Fmoc Aza-Peptide Michael Acceptor Unit for Solid Phase 
Inhibitor Synthesis. Reagents and conditions:  a) NH2NH2, ether.  b) t-butylbromoacetate, 




Solid phase synthesis of the aza-peptide Michael acceptor inhibitors proceeds 
from the C-terminal end using the Wang resin, which leaves a C-terminal carboxylic acid 
upon cleavage from the resin.  For each P3’ amino acid, the three non-prime sequences 
can be synthesized in parallel through the addition of the AAsp precursor.  At this point, a 
third of the resin is divided out and carried forward to the Z-Asp-Glu-Val-AAsp 
sequence.  The rest of the resin is carried on to the Z-Leu-Glu-Thr-AAsp and Z-Ile-Glu-
Thr-AAsp sequences, and is split in half for the final amino acid couplings.  The amino 
acid couplings are carried out with diisopropylcarbonyldiimidazole (DIC) and HOBT, 
and the Fmoc group is removed with 20% piperidine in DMF.  Final inhibitor cleavage 
from the resin and deblocking of the t-butyl side chains occurs through treatment with a 
TFA solution.  The Kaiser test for free amines is performed between each coupling and 
Fmoc deblocking step to confirm the completeness of reaction.  The general solid phase 















Figure 3.7.  General Solid Phase Synthesis Method with the Wang Resin. Reagents and 
conditions:  a) DIPCDI, DMAP, DMF.  B) 20% piperidine in DMF.  C) DIC, HOBT, 




Results and Discussion 
 
 The inhibition rate constants of the aza-peptide Michael acceptor inhibitors can be 
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The inhibition rates for this new series of aza-peptide Michael acceptor inhibitors 
are lower than the best of the previously discovered inhibitors.  There could be several 
explanations for this phenomenon.  First, the S3’ pocket of caspases could be solvent 
exposed and not prone to binding amino acid side chains.  Second, the P3’ side chain 
could be binding in a way that is unproductive to inhibition.  A third issue is the choice of 
the Wang resin that produces a C-terminal carboxylic acid.  It is possible that a C-
terminal amide, which mimics a continuing peptide chain, could be a better fit for the S3’ 
site.   
Despite the lower inhibition rates, conclusions can still be drawn from the 
inhibition results.  As expected, caspases -3 and -7 prefer the Asp-Glu-Val-AAsp 
sequence, caspase-6 prefers the Ile-Glu-Thr-AAsp sequence, and caspase-8 prefers the 
Leu-Glu-Thr-AAsp slightly over the Ile-Glu-Thr-AAsp sequence.  These results correlate 
well to the known P4 to P1 preferences of caspases.  Interestingly, all of the caspases, 
with the exception of caspase-7, prefer a P3’ Leu residue in the inhibitor of their 
preferred sequence.   
Caspase-3:  The caspase-3 P3’ preference is Leu > Glu ~ Lys > Phe ~ Ala. 
Caspase-6:  The caspase-6 P3’ preference is Leu > Glu > Phe > Lys > Ala. 
Caspase-7:  The caspase-7 P3’ preference is Lys > Leu > Glu > Phe ~ Ala. 




Selectivity of Aza-Peptide Michael Acceptor Inhibitors Among Caspases.   
Caspase-3 and -7.  Because caspases-3 and -7 both prefer the sequence Z-Asp-
Glu-Val-AAsp, differentiating between the two enzymes can be difficult.  Inhibitor 11 
with a P3’ Leu residue is the most specific for caspase-3 over -7 (12:1).  None of the 
inhibitors in the series were more potent for caspase-7 than -3. 
Caspase-6 and -8.  Because the sequence preferences of caspases -6 and -8 are so 
similar (P4 Ile vs. Leu), selectivity between the two enzymes can be difficult.  There were 
no inhibitors in the series that are very selective for caspase -6 over -8, with the most 
selective being inhibitor 21 with a P3’ Leu (2.6:1).  This is a result of the fact that 
caspase-8 is reasonably inhibited by the caspase-6 sequence Z-Ile-Glu-Thr-AAsp.  
Several of the inhibitors were selective for caspase-8 over caspase-6, including inhibitor 
16 with a P3’ Leu (16:1), inhibitor 15 with a P3’ Ala (37:1), and inhibitor 14 with a P3’ 
Phe (33:1). 
Stability of the Aza-Peptide Michael Acceptor Inhibitors.  We have previously 
observed that some of the Michael acceptor inhibitors react with the thiol DTT required 
for cysteine protease activity in kinetic assays.  Stability of the inhibitors to thiol reaction 
is dependant on the P’ substituents of the inhibitor.  These Michael acceptor inhibitors 
with P’ dipeptides showed no instability over the time course of the kinetic experiments, 






 We were successful in the solid phase synthesis of aza-peptide Michael acceptor 
inhibitors.  Caspases -3, -6, -7, and -8 all preferred a Leu residue in the P3’ position, 
suggesting that this region of caspases may be conserved.  We were able to achieve 
modest selectivity between some of the caspases.  One future experiment would be to 
perform the solid phase synthesis on the Rink resin, which leaves a C-terminal amide, to 
see if inhibitor potency is increased.  An aza-peptide epoxide unit could also be 
synthesized in order to make aza-peptide epoxide inhibitors for caspases.  Aza-peptide 
epoxide and Michael acceptor inhibitors for other clan CD enzymes (gingipains, 





Enzyme Assays.  Caspases -3, -6, -7, and -8 were obtained from the laboratory of Guy 
Salvesen (Burnham Institute, La Jolla, CA) and stored at -78 oC prior to use.  The 
fluorogenic substrate Ac-DEVD-AMC (AMC, excitation λ = 360 nm, emission λ = 405 
nm) was purchased from Bachem Biosciences Inc. (King of Prussia, PA).  Caspase 
inhibition rates were determined by the progress curve method.  The fluorescence was 
detected with a Tecan Spectraflour Microplate Reader (Tecan US, Research Triangle 
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Park, NC).  Enzyme-substrate KM values, used to correct for substrate competition, were 
determined in the laboratory of Guy Salvesen. 
Caspase-3.  Caspase-3 was diluted to 2 nM in the assay buffer 20 mM Pipes, 
0.1% CHAPS, 10% sucrose, 100 mM NaCl, 1 mM EDTA, 10 mM DTT, pH 7.2, and was 
activated for 10 min. at 37 oC.  The inhibitor in DMSO was diluted with assay buffer 
containing the substrate Ac-DEVD-AMC (final concentration 0.10 mM, KM = 9.7 µM).  
At t = 0 s, the enzyme was added to the mixture (final [E] = 1.0 nM, [I] = 2.5 µM to 0.25 
mM).  The reaction was monitored over 15 min by following the change in fluorescence 
at 465 nm.  Inhibition rates were performed in duplicate and the error ranges are reported. 
Caspase-6.  Caspase-6 was diluted to 20 nM in the assay buffer 20 mM Pipes, 
0.1% CHAPS, 10% sucrose, 100 mM NaCl, 1 mM EDTA, 10 mM DTT, pH 7.2, and was 
activated for 10 min at 37 oC.  The inhibitor in DMSO was diluted with assay buffer 
containing the substrate Ac-DEVD-AMC (final concentration 0.10 mM, KM = 246 µM).  
At t = 0 s, the enzyme was added to the mixture (final [E] = 10.0 nM, [I] = 7.8 µM to 
0.25 mM).  The reaction was monitored over 15 min by following the change in 
fluorescence at 465 nm.  Inhibition rates were performed in duplicate and the error ranges 
are reported. 
Caspase-7.  Caspase-7 was diluted to 2 nM in the assay buffer 20 mM Pipes, 
0.1% CHAPS, 10% sucrose, 100 mM NaCl, 1 mM EDTA, 10 mM DTT, pH 7.2, and was 
activated for 10 min at 37 oC.  The inhibitor in DMSO was diluted with assay buffer 
containing the substrate Ac-DEVD-AMC (final concentration 0.10 mM, KM = 23 µM).  
At t = 0 s, the enzyme was added to the mixture (final [E] = 1.0 nM, [I] = 12.5 µM to 
0.25 mM).  The reaction was monitored over 15 min by following the change in 
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fluorescence at 465 nm.  Inhibition rates were determined in duplicate and the error 
ranges are reported. 
Caspase-8.  Caspase-8 was diluted to 100 nM in the assay buffer 20 mM Pipes, 
0.1% CHAPS, 10% sucrose, 100 mM NaCl, 1 mM EDTA, 10 mM DTT, pH 7.2, and was 
activated for 10 min at 37 oC.  The inhibitor in DMSO was diluted with assay buffer 
containing the substrate Ac-DEVD-AMC (final concentration 0.10 mM, KM = 6.79 µM).  
At t = 0 s, the enzyme was added to the mixture (final [E] = 50.0 nM, [I] = 25 µM to 0.25 
mM).  The reaction was monitored over 15 min by following the change in fluorescence 
at 465 nm.  Inhibition rates were performed in duplicate and the error ranges are reported. 
 
Materials and Methods.  Z-amino acid derivatives were purchased from Bachem 
Biosciences Inc. (King of Prussia, PA).  The Wang resin (100-200 mesh) and Fmoc-
protected amino acids were purchased from Calbiochem-Novabiochem (San Diego, CA).   
 
 Fmoc-NH-NH2.  Fmoc-chloroformate (1 g, 3.86 mmol) was dissolved in ether 
(20 mL) and cooled to 0 oC.  Hydrazine (0.39 g, 12.2 mmol) was mixed with ether (20 
mL) and added to the reaction.  A white precipitate formed immediately, and the reaction 
was allowed to stir for 4 hrs.  The reaction was concentrated under reduced pressure and 
the solid residue taken up in water, filtered, and dried in vacuo to yield Fmoc-NH-NH2 
(828 mg, 84% yield).  1H NMR (d6-acetone): 2.01-2.10 (m, 2H), 4.22-4.30 (t, 1H), 4.35-
4.42 (d, 2H), 7.29-7.46 (dt, 4H), 7.70-7.78 (d, 2H), 7.85-7.89 (d, 2H), 8.88-8.98 (s, 1H). 
 Fmoc-NH-NH-CH2-COO-t-Bu.  Fmoc-NH-NH2 (880 mg, 3.46 mmol) was 
dissolved in DMF (10 mL) and cooled to -20 oC.  NMM (349 mg, 3.46 mmol) was added 
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to the reaction, followed by t-butyl bromoacetate (877 mg, 4.50 mmol).  The reaction was 
allowed to stir in the cold for 30 min, then at room temperature overnight.  The reaction 
was concentrated under reduced pressure, and the crude product was purified by column 
chromatography (8% MeOH, 20% EtOAc, 73% CH2Cl2) to yield Fmoc-NH-NH-CH2-
COO-t-Bu (556 mg, 44% yield).  1H NMR (d6-acetone): 1.38-1.47 (s, 9H), 3.43-3.54 (d, 
2H), 4.18-4.27 (t, 1H), 4.30-4.37 (d, 2H), 4.49-4.57 (m, 1H), 7.27-7.45 (dt, 4H), 7.64-
7.74 (d, 2H), 7.81-7.89 (d, 2H), 7.90-7.99 (s, 1H). 
 Fmoc-AAsp(O-tBu)-CH=CH-COOH.  Fumaric acid (275 mg, 2.37 mmol) was 
coupled to Fmoc-NH-NH-CH2-COO-t-butyl (459 mg, 1.19 mg) following the general 
mixed anhydride procedure.  The crude product was purified by column chromatography 
(8% MeOH, 20% EtOAc, 73% CH2Cl2) and recrystallized from ether/hexanes to yield 
Fmoc-AAsp(O-tBu)-CH=CH-COOH (247 mg, 45% yield).  1H NMR (d6-acetone): 0.93-
0.99 (s, 9H), 3.46-3.51 (d, 2H), 3.79-3.85 (t, 1H), 3.92-4.00 (s, 1H), 6.23-6.26 (d, 2H), 
6.72-6.79 (d, 1H), 6.83-6.91 (t, 2H), 6.93-7.00 (t, 2H), 7.20-7.29 (s, 2H), 7.40-7.46 (d, 
2H), 10.10-10.20 (s, 1H).  HRMS (ESI) Calcd 466.  Observed m/z  [M+ H]+ 467.3.  
 
General Methods for Solid Phase Peptide Synthesis.  Synthesis of the aza-peptide 
Michael acceptor inhibitors was carried out manually on the Wang resin in a 12 mL Bio-
spin chromatography column.  Fmoc-amino acids were used with t-butyl-protected side 
chains (Asp, Glu, Thr, Lys).  The Fmoc-AAsp(O-tBu)-CH=CH-COOH was synthesized 
as described above prior to incorporation into the solid phase synthesis. 
 Loading of the Resin with the First Amino Acid Residue.  The resin (300 mg, 
0.267 mmol, 0.89 mmol reactive sites/g) was allowed to swell in DMF for 30 min.  The 
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Fmoc-AA-OH (10 eq to resin, 2.67 mmol) was dissolved in CH2Cl2 with a few drops of 
DMF and cooled in an ice bath.  Diisopropylcarbodiimide (DIC) (73.7 mg, 0.534 mmol, 
2 eq to resin) and DMAP (3 mg, 0.0267 mmol, 0.1 eq to resin) were added to the Fmoc-
AA-OH solution and the reaction stirred for 20 min.  The CH2Cl2 was evaporated in 
vacuo and the residue dissolved in minimal DMF.  This solution was added to the resin 
and allowed to react for 2 hrs to overnight.  The resin was then drained and washed with 
DMF (5 mL) and CH2Cl2 (5 mL).  A second cycle was performed to ensure completion 
of reaction. 
 Fmoc Cleavage.  Fmoc is cleaved from the N-terminal amino acid attached to the 
resin by the addition of 20% piperidine in DMF to the resin.  The solution (2 mL) was 
added and drained in 3-three minute cycles.  The resin was then washed with DMF (5 
mL) and CH2Cl2  (5 mL). 
 Coupling Additional Amino Acid Residues to the Growing Chain.  Fmoc-AA-
OH (2 eq to resin, 0.534 mmol) was dissolved in CH2Cl2 with a few drops of DMF and 
cooled in an ice bath.  Diisopropylcarbodiimide (DIC) (74 mg, 0.534 mmol, 2 eq to resin) 
and HOBT (73 mg, 0.534 mmol, 2 eq to resin) were added to the Fmoc-AA-OH solution 
and the reaction stirred for 20 min.  The CH2Cl2 was evaporated in vacuo and the residue 
dissolved in minimal DMF.  This solution was added to the resin and allowed to react for 
2 hrs to overnight.  The resin was then drained and washed with DMF (5 mL) and CH2Cl2 
(5 mL) .  A second coupling cycle was performed to ensure completion of reaction. 
 The Kaiser Test.  The Kaiser test determines the presence or absence of free 
amines.  It is performed after every amino acid coupling and Fmoc cleavage step to 
confirm completion of the reaction.  A few beads of resin are sampled and washed with 
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EtOH.  The beads were treated with two drops of a ninhydrin solution (0.5 g ninhydrin in 
10mL EtOH), two drops of a phenol solution (8 g in 2 mL EtOH), and two drops of 1 
mM KCN (aq.) in pyridine.  The mixture was heated to 120 oC for 5 min.  A dark blue 
solution indicates the presence of a free amine, which is expected after a Fmoc-
deblocking step.  A yellow/brown solution indicates the absence of free amines, which is 
expected after an amino acid coupling step. 
 Cleavage of Inhibitor from Resin and Deprotection of t-Butyl Protecting 
Groups.   The resin was washed with EtOH and dried under reduced pressure.  A 
cocktail of 95% TFA, 2.5% H2O, and 2.5% TIS was added to the resin and allowed to 
react for 2 hrs.  The resin was filtered and washed with the TFA solution, and the 
combined TFA solutions were concentrated in vacuo.  The residue was recrystallized 
with ether/hexanes to yield the inhibitors as white powders. 
 N2-(N-Benzyloxycarbonylaspartylglutamylvalyl)-N1-carboxymethyl-N1-trans-
(3-(1-carboxyethylcarbamoyl)methylcarbamoylacryloyl)hydrazine (Z-Asp-Glu-Val-
AAsp-trans-CH=CH-CO-Gly-Ala-OH).  Yield 113 mg, 53%.  1H NMR (d6-DMSO): 
0.82-0.97 (dd, 6H, J = 5, 9 Hz), 1.19-1.28 (d, 3H, J = 5 Hz), 1.68-1.83 (m, 2H), 2.17-2.27 
(m, 2H), 2.51-2.58 (m, 1H), 2.60-2.68 (m, 2H), 3.79-3.89 (d, 2H, J = 5 Hz), 4.13-4.23 
(m, 4H), 4.29-4.40 (m, 2H), 4.97-5.04 (s, 2H), 7.25-7.38 (m, 5H), 7.52-7.62 (dd, 2H, J = 
3, 6 Hz), 8.10-8.16 (m, 1H), 8.23-8.32 (m, 2H), 8.65-8.80 (m, 1H), 8.92-8.98 (s, 1H).  
HRMS (ESI) Calcd 793.27679.  Observed m/z [M – 2H]- 790.9. 
N2-(N-Benzyloxycarbonylleucylglutamylthreonyl)-N1-carboxymethyl-N1-
trans-(3-(1-carboxyethylcarbamoyl)methylcarbamoylacryloyl)hydrazine (Z-Leu-
Glu-Thr-AAsp-trans-CH=CH-CO-Gly-Ala-OH).  Yield 52 mg, 49 %.  1H NMR (d6-
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DMSO): 0.77-0.90 (dd, 6H, J = 4, 8 Hz), 0.99-1.07 (d, 3H, J = 3 Hz), 1.20-1.27 (d, 3H, J 
= 6 Hz), 1.53-1.62 (m, 2H), 1.82-1.91 (m, 1H), 2.18-2.26 (m, 2H), 2.28-2.32 (m, 2H), 
3.66-3.75 (m, 2H), 3.78-3.82 (d, 2H, J = 6 Hz), 4.13-4.22 (q, 1H, J = 6 Hz), 4.31-4.38 (m, 
4H), 4.96-5.01 (s, 2H), 7.25-7.34 (m, 5H), 7.38-7.44 (m, 2H), 7.90-7.99 (m, 1H), 8.01-
8.04 (s, 1H), 8.09-8.16 (m, 1H), 8.22-8.31 (m, 1H), 8.53-8.57 (m, 1H).  HRMS (ESI) 
Calcd 793.31321.  Observed m/z  [M+ H – 44 CO2]+ 751.5. 
N2-(N-Benzyloxycarbonylisoleucylglutamylthreonyl)-N1-carboxymethyl-N1-
trans-(3-(1-carboxyethylcarbamoyl)methylcarbamoylacryloyl)hydrazine (Z-Ile-Glu-
Thr-AAsp-trans-CH=CH-CO-Gly-Ala-OH).  Yield 60 mg, 57%.  1H NMR (d6-
DMSO): 0.73-0.91 (m, 6H), 1.00-1.08 (m, 3H), 1.11-1.14 (m, 2H), 1.21-1.27 (d, 3H, J = 
6 Hz), 1.60-1.76 (m, 2H), 1.84-1.90 (m, 2H), 2.21-2.29 (s, 1H), 2.50-2.53 (m, 1H), 3.68-
3.76 (m, 2H), 3.82-3.91 (m, 2H), 4.14-4.22 (m, 4H), 4.34-4.40 (m, 1H), 4.97-5.01 (s, 
2H), 7.25-7.32 (m, 2H), 7.32-7.37 (m, 5H), 8.02-8.06 (s, 1H), 8.09-8.18 (m, 2H), 8.23-
8.28 (m, 2H).  HRMS (ESI) Calcd 793.31321.  Observed m/z [M + H – 44 CO2]+ 751.4. 
N2-(N-Benzyloxycarbonylaspartylglutamylvalyl)-N1-carboxymethyl-N1-trans-
(3-(1-carboxy-2-phenylethylcarbamoyl)methylcarbamoylacryloyl)hydrazine (Z-Asp-
Glu-Val-AAsp-trans-CH=CH-CO-Gly-Phe-OH).  Yield 39 mg, 56 %.  1H NMR (d6-
DMSO): 0.80-0.93 (m, 6H), 1.83-1.94 (m, 2H), 2.18-2.27 (m, 2H), 2.58-2.62 (m, 1H), 
2.64-2.68 (m, 2H), 3.82-3.92 (m, 2H), 4.14-4.23 (m, 2H), 4.30-3.33 (m, 4H), 4.98-5.04 
(s, 4H), 7.25-7.42 (m, 10H), 7.52-7.63 (dd, 2H, J = 5, 8 Hz), 7.90-7.94 (s, 2H), 8.00-8.03 
(s, 1H), 8.10-8.15 (d, 2H, J = 6 Hz).  HRMS (ESI) Calcd 869.30811.  Observed m/z  [M 





(Z-Leu-Glu-Thr-AAsp-trans-CH=CH-CO-Gly-Phe-OH).  Yield 24 mg, 34%.  1H 
NMR (d6-DMSO): 0.78-0.91 (m, 6H), 0.94-0.97 (d, 3H, J = 3 Hz), 1.52-1.64 (m, 2H), 
1.67-1.76 (m, 2H), 2.18-2.26 (m, 2H), 2.28-2.31 (m, 2H), 3.64-3.70 (m, 2H), 3.97-4.05 
(m, 2H), 4.10-4.18 (m, 1H), 4.32-4.43 (m, 4H), 4.96-5.02 (s, 4H), 7.28-7.35 (m, 10H), 
7.38-7.44 (dd, 2H, J = 1, 6 Hz), 7.98-8.23 (m, 5H).  HRMS (ESI) Calcd 869.34453.  
Observed m/z [M – H]- 868.1 
N2-(N-Benzyloxycarbonylisoleucylglutamylthreonyl)-N1-carboxymethyl-N1-
trans-(3-(1-carboxy-2-phenylethylcarbamoyl)methylcarbamoylacryloyl)hydrazine 
(Z-Ile-Glu-Thr-AAsp-trans-CH=CH-CO-Gly-Phe-OH).  Yield 19 mg, 27%.  1H NMR 
(d6-DMSO): 0.71-0.81 (m, H), 0.82-0.91 (m, 2H), 0.99-1.06 (m, 3H), 1.59-1.72 (m, 2H), 
2.15-2.25 (m, 2H), 2.50-2.55 (m, 1H), 3.81-3.89 (m, 2H), 4.08-4.16 (m, 2H), 4.17-4.20 
(m, 1H), 4.32-4.44 (m, 4H), 4.96-5.02 (m, 4), 7.16-7.24 (m, 2H), 7.30-7.36 (m, 10H), 
7.75-7.81 (m, 1H), 7.99-8.10 (m, 3H),  8.15-8.17 (m, 1H).  HRMS (ESI) Calcd 
869.34453.  Observed m/z [M – H]- 868.3 
N2-(N-Benzyloxycarbonylaspartylglutamylvalyl)-N1-carboxymethyl-N1-trans-
(3-(1-carboxy-3-methylbutylcarbamoyl)methylcarbamoylacryloyl)hydrazine (Z-
Asp-Glu-Val-AAsp-trans-CH=CH-CO-Gly-Leu-OH).  Yield 24.71 mg, 33%.  1H 
NMR (d6-DMSO): 0.76-0.91 (dd, 12H, J = 5, 8 Hz), 1.53-1.66 (m, 2H), 1.69-1.76 (p, 1H, 
J = 4 Hz), 1.86-1.97 (m, 2H), 2.17-2.28 (m, 2H), 2.58-2.62 (p, 1H, J = 3 Hz), 2.62-2.66 
(d, 2H, J = 3 Hz), 3.78-3.87 (m, 2H), 4.12-4.19 (s, 2H), 4.29-4.39 (m, 4H), 4.98-5.02 (s, 
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2H), 7.26-7.35 (m, 5H), 7.59-7.64 (d, 2H, J = 6 Hz), 7.89-8.21 (m, 5H).  HRMS (ESI) 
Calcd 835.32377.  Observed m/z [M – 2]- 833.3. 
N2-(N-Benzyloxycarbonylleucylglutamylthreonyl)-N1-carboxymethyl-N1-
trans-(3-(1-carboxy-3-methylbutylcarbamoyl)methylcarbamoylacryloyl)hydrazine 
(Z-Leu-Glu-Thr-AAsp-trans-CH=CH-CO-Gly-Leu-OH).  Yield 29.69 mg, 40 %.  1H 
NMR (d6-DMSO): 0.76-0.93 (dd, 12H, J = 5, 8 Hz), 0.93-0.98 (d, 3H, J = 4 Hz), 1.52-
1.62 (m, 4H), 1.83-1.95 (p, 2H, J = 3 Hz), 2.16-2.28 (m, 4H), 2.39-2.45 (m, 2H), 3.67-
3.74 (s, 2H), 3.76-3.86 (m, 2H), 4.18-4.22 (m, 1H), 4.27-4.40 (m, 4H), 4.94-5.07 (s, 2H), 
7.23-7.37 (m, 5H), 7.29-7.46 (d, 2H, J = 6 Hz), 7.68-7.75 (s, 1H), 7.81-7.86 (d, 1H, J = 6 
Hz), 7.98-9.13 (m, 3H), 8.24-8.31 (s, 1H), 8.61-8.68 (d, 1H, J = 6 Hz), 12.10-12-60 (m, 
3H).  HRMS (ESI) Calcd 835.36019.  Observed m/z [M – H]- 834.2. 
N2-(N-Benzyloxycarbonylisoleucylglutamylthreonyl)-N1-carboxymethyl-N1-
trans-(3-(1-carboxy-3-methylbutylcarbamoyl)methylcarbamoylacryloyl)hydrazine 
(Z-Ile-Glu-Thr-AAsp-trans-CH=CH-CO-Gly-Leu-OH).  Yield 21.35 mg, 29%.  1H 
NMR (d6-DMSO): 0.72-0.89 (dd, 12H, J = 5, 8 Hz), 0.97-1.16 (m, 5H), 1.33-1.50 (m, 
2H), 1.53-1.62 (m, 2H), 1.67-1.74 (m, 2H), 1.84-1.92 (p, 1H, J = 3 Hz), 2.18-2.28 (s, 
1H), 2.50-2.55 (q, 1H, J = 3 Hz), 3.78-3.87 (m, 2H), 4.18-4.23 (m, 1H), 4.28-4.39 (m, 
4H), 4.94-5.02 (s, 2H), 7.26-7.37 (m, 7H), 7.98-8.15 (m, 5H). HRMS (ESI) Calcd 
835.36019.  Observed m/z [M – H]- 834.0. 
N2-(N-Benzyloxycarbonylaspartylglutamylvalyl)-N1-carboxymethyl-N1-trans-
(3-(1-carboxy-3-carboxypropylcarbamoyl)methylcarbamoylacryloyl)hydrazine (Z-
Asp-Glu-Val-AAsp-trans-CH=CH-CO-Gly-Glu-OH).  Yield 10.72 mg, 14%.  1H 
NMR (d6-DMSO): 0.80-0.89 (dd, 6H, J = 2, 6 Hz), 1.96-2.08 (m, 4H), 2.16-2.29 (m, 4H), 
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2.39-2.43 (m, 1H), 2.56-2.62 (m, 2H), 3.72-3.78 (d, 2H, J = 6 Hz), 4.13-4.21 (m, 2H), 
4.27-4.40 (m, 4H), 4.98-5.02 (s, 2H), 7.24-7.36 (m, 5H), 7.51-7.64 (dd, 2H, J = 6, 8 Hz), 
7.89-7.95 (d, 2H, J = 5 Hz), 8.01-8.05 (s, 1H), 8.08-8.12 (d, 1H, J = 6 Hz), 8.16-8.22 (m, 




AAsp-trans-CH=CH-CO-Gly-Glu-OH).  Yield 4.45 mg, 6 %.  1H NMR (d6-DMSO): 
0.78-0.90 (dd, 6H, J = 5, 8 Hz), 0.99-1.04 (m, 3H), 1.69-1.80 (m, 2H), 1.84-1.96 (m, 2H), 
2.16-2.29 (m, 4H), 3.71-3.79 (m, 2H), 3.96-4.06 (m, 2H), 4.12-4.24 (m, 1H), 4.21-4.38 
(m, 4H), 4.96-5.02 (s, 2H), 7.24-7.36 (m, 5H), 7.40-7.46 (m, 2H), 7.90-7.95 (m, 2H), 




AAsp-trans-CH=CH-CO-Gly-Glu-OH).  Yield 6.80 mg, 9 %.  1H NMR (d6-DMSO): 
0.73-0.88 (m, 6H), 0.99-1.06 (m, 3H), 1.65-1.79 (m, 4H), 1.85-1.98 (m, 4H), 2.27-2.31 
(s, 1H), 2.61-2.65 (m, 1H), 3.69-3.78 (m, 2H), 4.11-4.25 (m, 4H), 4.31-4.39 (m, 1H), 
4.98-5.02 (s, 2H), 7.25-7.30 (m, 2H), 7.31-7.38 (m, 5H), 7.91-7.94 (s, 1H), 8.00-8.10 (m, 
2H), 8.16-8.22 (m, 1H).  HRMS (ESI) Calcd 851.31067.  Observed m/z [M + H]+ 852.2. 
N2-(N-Benzyloxycarbonylaspartylglutamylvalyl)-N1-carboxymethyl-N1-trans-
(3-(1-carboxy-5-aminopentylcarbamoyl)methylcarbamoylacryloyl)hydrazine (Z-
Asp-Glu-Val-AAsp-trans-CH=CH-CO-Gly-Lys-OH).  Yield 45.56 mg, 53%.  1H 
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NMR (d6-DMSO): 0.82-0.91 (d, 6H, J = 5 Hz), 1.27-1.36 (m, 2H), 1.45-1.52 (m, 2H), 
1.65-1.72 (m, 2H), 2.17-2.27 (m, 2H), 2.52-2.62 (p, 1H, J = 3 Hz), 2.62-2.69 (m, 2H), 
3.64-3.99 (m, 6H), 4.11-4.20 (m, 2H), 4.28-4.39 (m, 4H), 4.99-5.02 (s, 2H), 7.26-7.37 
(m, 7H), 7.56-7.68 (m, 3H), 7.90-7.94 (s, 2H), 8.18-8.28 (m, 2H), 12.10-12.50 (m, 4H).  
HRMS (ESI) Calcd 964.32735.  Observed m/z [M + H – 114 TFA]+ 851.5. 
N2-(N-Benzyloxycarbonylleucylglutamylthreonyl)-N1-carboxymethyl-N1-
trans-(3-(1-carboxy-5-aminopentylcarbamoyl)methylcarbamoylacryloyl)hydrazine 
(Z-Leu-Glu-Thr-AAsp-trans-CH=CH-CO-Gly-Lys-OH).  Yield 30.32 mg, 36%.  1H 
NMR (d6-DMSO): 0.79-0.90 (dd, 6H, J = 3, 6 Hz), 0.98-1.06 (m, 3H), 1.26-1.33 (m, 2H), 
1.53-1.62 (m, 2H), 1.65-1.75 (m, 2H), 1.80-1.89 (p, 1H, J = 6 Hz), 2.21-2.31 (m, 2H), 
2.51-2.55 (m, 2H), 2.69-2.79 (m, 4H), 3.77-3.84 (m, 2H), 3.84-3.90 (m, 2H), 3.98-4.08 
(m, 1H), 4.12-4.22 (m, 4H), 4.96-5.01 (s, 2H), 7.26-7.35 (m, 5H), 7.38-7.44 (d, 2H, J = 5 
Hz), 7.56-7.67 (m, 3H), 7.91-7.93 (s, 1H), 8.03-8.11 (m, 1H), 8.16-8.28 (m, 3H).  HRMS 
(ESI) Calcd 964.36373.  Observed m/z [M + H – 114 TFA]+ 852.0. 
N2-(N-Benzyloxycarbonylisoleucylglutamylthreonyl)-N1-carboxymethyl-N1-
trans-(3-(1-carboxy-5-aminopentylcarbamoyl)methylcarbamoylacryloyl)hydrazine 
(Z-Ile-Glu-Thr-AAsp-trans-CH=CH-CO-Gly-Lys-OH).  Yield 27.59 mg, 32%.  1H 
NMR (d6-DMSO): 0.72-0.90 (m, 6H), 0.93-0.98 (m, 2H), 1.00-1.07 (t, 3H, J = 6 Hz), 
1.26-1.34 (m, 2H), 1.43-1.55 (m, 2H), 1.64-1.75 (m, 2H), 1.79-1.90 (m, 2H), 2.21-2.30 
(s,1H), 2.48-2.56 (m, 1H), 2.68-2.78 (m, 2H), 3.76-3.82 (d, 2H, J = 6 Hz), 3.82-3.92 (m, 
4H), 4.20-4.23 (m, 1H), 4.96-5.02 (s, 2H), 7.24-7.30 (m, 2H), 7.30-7.36 (m, 5H), 7.57-
7.68 (m, 3H), 7.99-8.11 (m, 2H), 8.18-8.27 (m, 2H).  HRMS (ESI) Calcd 964.36373.  





AZA-PEPTIDE EPOXIDES AND MICHEAL ACCEPTORS AS INHIBITORS OF 





Gingipains.  Gingipains R and K are cysteine proteases isolated from the bacterium 
Porphyromonas gingivalis.  P. gingivalis is a Gram-negative, anaerobic, nonmotile short 
rod bacteria which has been determined to be a major player in periodontal disease.  
Periodontitis is an inflammatory process induced by bacteria, which results in the 
destruction of connective tissue and bone that support the teeth.  P. gingivalis expresses 
as many as eight virulence factors including Gingipains R and K, and other proteases and 
co-factors.  Gingipains are responsible for 85% of the proteolytic activity present in P. 
gingivalis.76   
 Gingipains R and K are two important virulence factors in the progression of 
periodontitis.  Gingipain R contributes to the bacterial adhesion to the host tissue through 
processing of fimbrilin, a cell surface protein.77  Gingipains R and K cleave and 
inactivate interleukin-1β, interleukin-6, interleukin-8,  and TNFα, which enables the 
bacteria to evade the host immune response.78,79  Gingipain R activates Factor X, which 
leads to blood coagulation and sepsis, and explains the link between periodontitis and 
coronary disease.80  Gingipain R is responsible for the type I collagenase activity present 
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in P. gingivalis.81  The gingipains lyse erythrocytes and iron-binding proteins, which 
provides amino acids and iron as nutrition for the bacterium.82,83   
Gingipains R and K are most active in the presence of reducing agents and above 
pH 8, which are the conditions of the periodontal pocket during advanced colonization of 
P. gingivalis.84  The gingipains are excreted in a soluble form into bacterial culture 
media, as well as associated with bacterial cell membranes and vesicles.85 
Gingipain Specificity.  Gingipain R cleaves specifically after a P1 arginine 
residue.  There are two forms of gingipain R known as HRgpA and RgpB.15  These two 
forms have nearly identical catalytic domains.  A few amino acid substitutions in the 
catalytic domain account for the small differences in their specificity.  HRgpA contains 
additional hemagglutinin/adhesion domains, which seem to play a small role in substrate 
binding.  Gingipain R is capable of autolysis in its propeptide form.  The presence of 
glycyl-glycine is shown in increase gingipain R activity, which is not seen in any other 
enzyme.86  Gingipain R has a preference for hydrophobic amino acids in the P2 and P3 
positions. 
 Gingipain K (Kgp) cleaves specifically after a P1 lysine residue.  The enzyme 
accepts a wide variety of amino acids in the P2 position, excluding lysine and arginine.  
Gingipain K will not cleave after a lysine at the N-terminus of a peptide.  Unlike 
gingipain R, gingipain K is inhibited by the addition of glycyl- glycine.84  Gingipain K is 
not auto-proteolytic, but is processed and activated by gingipain R. 
Gingipain Structure.  The crystal structure of Gingipain R (RgpB, pdb 1cvr) 
demonstrates a similar fold to caspases-1 and -3, representative clan CD cysteine 
proteases.76  The deep S1 pocket formed by Val242 and Thr209 harbors the Asp163, 
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which binds the arginine guanidino group and accounts for the stringent P1 specificity.  
The guanidinium nitrogens are both close enough to the Met288 S to participate in 
hydrogen bonding.  In gingipain K, this Met288 is replaced by a Tyr, which explains 
gingipain K’s preference for a lysine ammonium.  This is a key difference between 
gingipains R and K.  The backbone amide nitrogens of Gly212 and Cys244 form the 
oxyanion hole of RgpB which stabilizes the intermediate formed from the attack of 
Cys244.  A calcium ion is bound just below the S1 pocket, stabilizing this binding site.  
























































































Figure 4.1.  Substrate Binding Mode of Gingipain R.76 
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Gingipain Inhibitors.  There are few inhibitors of the gingipains, with almost no 
inhibitors specifically designed for the enzymes.  The epoxide inhibitor E64, a natural 
product inhibitor of cysteine proteases, is a modest inhibitor of gingipain R, while 
gingipain K is not inhibited.84  Halomethylketones and aldehydes with P1 Lys and P1 
Arg have been shown to be inhibitors of gingipains K and R, respectively.76  A natural 
product non-covalent inhibitor of gingipain R has been reported with a KI in the 
nanomolar range.87 
 
Clostripain.  Clostridium hystoliticum is a Gram-positive bacterium involved in gas 
gangrene syndrome.88  The presence of a proteinase in the culture filtrate of Clostridium 
hystolyticum was first detected in the 1930’s, and the enzyme was isolated and 
characterized as clostripain in 1948.88  Clostripain has strict substrate specificity, cleaving 
only after Arg or Lys residues.  It further prefers Arg over Lys, and has been shown to 
cleave only after Arg when Arg and Lys are both present in a substrate peptide.89  This 
preference has been attributed to higher KM and lower kcat values of Lys peptide 
substrates.89  This preference for Arg over Lys is much less pronounced in inhibitors than 
substrates.90  Clostripain will also readily cleave the Arg-Pro bond, which is difficult for 
trypsin, a serine protease with similar specificity.   
Clostripain Inhibitors.  A number of inhibitors containing P1 Arg and Lys along 
with various reversible and irreversible warheads have been proven potent inactivators of 
clostripain.90  These include aldehydes, chloromethylketones, aziridinyl peptides, and 
sulfonium methyl ketones.  Similar to the gingipains, few inhibitors have been designed 






Given the success of aza-peptide epoxide and Michael acceptor inhibitors for 
caspases, we turned our attention to extending this design to other clan CD enzymes, 
including the gingipains and clostripain.  This design involves a P1 ALys and AArg 
residue followed by the epoxide or Michael acceptor warhead as seen in Figure 4.2.  A 
Leu P2 residue was chosen along with a phenypropyl N-capping group for ease of 
synthesis, since the gingipains are tolerant of many amino acids at these positions.  A 
series of AOrn inhibitors were synthesized as precursors of the AArg inhibitors, and were 
also tested for inhibitory potency.  Varying functional groups are synthesized in the P1’ 
position of the inhibitors in order to discover the most potent inhibitor.  These inhibitors 
were synthesized and characterized by Zhao Zhao Li (unpublished), and the synthesis 























PhPr-Leu-ALys-EPS-COR PhPr-Leu-AArg-CH=CH-COR  





Results and Discussion 
 
 The series of inhibitors synthesized for the gingipains and clostripain can be seen 
in Table 4.1 along with their inhibitory potency.  The aza-peptide epoxide and Michael 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Gingipain K.  The ALys inhibitors were the most potent inhibitors for gingipain K, as 
was expected given the enzyme’s preference for a P1 Lys.  The ALys epoxides and 
Michael acceptors were about equipotent, with differences in potency depending more on 
the P1’ substituent than the type of warhead.  The most potent inhibitor in the series was 
the epoxide benzyl amide (4) with a rate constant of kobs = 6,210,000 M-1s-1, one of the 
highest rates of inhibition ever measured in the Powers laboratory.  The epoxide dibutyl 
amide 3 showed drastically lower potency than the other inhibitors, with the dibutyl 
amide probably disrupting the productive binding of the epoxide warhead to the enzyme.  
The series of inhibitors includes both P1’ monosubstituted amides and disubstituted 
amides.  Generally, gingipain K seemed to tolerate the disubstituted amides in Michael 
acceptor inhibitors better than in epoxides.  With the epoxide inhibitors the mono-
substituted amides display higher potency (4 vs. 6 or 3), whereas in the Michael acceptor 
inhibitors some of the disubstituted inhibitors are more potent (9 vs. 10 or 11).  There is 
possibly more flexibility in the binding of the Michael acceptors, which allows the two 
P1’ substituents in the di-substituted amides to bind appropriately without sacrificing the 
binding of the double bond.  The fact the Michael acceptors have two faces that are 
susceptible to thiol attack compared to one for epoxides could also explain this 
phenomenon, as demonstrated in Figure 4.3.  If the larger, disubstituted P1’ substituent 
binds in such a way that the double bond or epoxide warhead is turned in the active site, 
the double bond is still be able to inhibit through attack of the thiol on the other face, 
whereas the epoxide could not.  The tetrahydroquinoline inhibitor (16) is not as potent as 
other Michael acceptor disubstituted amides, most likely because of the rigidity of the 
ring system.  These inhibitors demonstrate that the S1’ site of gingipain K can 
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accommodate large aromatic groups, as can be seen in the Michael acceptor dinaphthyl 
inhibitor (15).  While some of the ALys inhibitors are more potent than others with 
gingipain K, all of the inhibitors are truly excellent inhibitors of gingipain K. 
 The gingipain K inhibitors are more effective inactivators of gingipain K than the 
gingipain R inhibitors for gingipain R.  In a recent paper, Bialas et al91 described the 
difference in the S3 subsites of gingipains K and R, stating that the gingipain K S3 site is 
deeper and could bind to bulky aromatics better than gingipain R.  It is possible that the 
phenylpropyl N-capping group on our inhibitors is engaging with the S3 subsite of 

























Double Bond Epoxide  




The AOrn inhibitors are similar to the ALys inhibitors, however the AOrn has one 
less methylene group in the side chain.  With the shortened side chain, these inhibitors 
are still good inactivators of gingipain K, although they are less potent than the ALys 
series.  The AOrn epoxide benzyl amide (24) is the best inhibitor of this series with 
gingipain K, which is consistent with the results of the ALys series.  The Michael 
acceptor P1’ preference is different than seen in the ALys series, with the P1’ethyl ester 
(26) having the greatest potency.  The shorter AOrn side chain could pull the inhibitor 
farther into the S1 pocket in order to make contact with the deeply situated Glu, orienting 
the inhibitors such that larger P1’ substituents are unable to bind as productively as in the 
ALys inhibitors.   
 As expected, the AArg inhibitors are only modest inhibitors of gingipain K.  
Generally, the epoxides are better inhibitors than the Michael acceptors in this series, and 
smaller P1’ groups are better tolerated by the enzyme. 
 
Gingipain R.  As expected, the AArg inhibitors are the most potent inhibitors we found 
for gingipain R.  While the rates of inhibition are not as high as the ALys with gingipain 
K, the AArg inhibitors are still excellent with gingipain R.  Unlike gingipain K, the 
Michael acceptor inhibitors are generally better than the epoxides, and the choice of 
warhead has a greater effect on potency than the choice of P1’ substituent.  The ethyl 
ester P1’ group is the best fit in both the epoxide and Michael acceptor inhibitors.  
Because of this, it appears that the S1’ pocket of gingipain R is less accommodating of 
larger substituents than gingipain K.   
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 The ALys and AOrn compounds proved to be much poorer inhibitors of gingipain 
R, with the ALys inhibitors being slightly more potent than the AOrn.  The best of the 
ALys inhibitors all are Michael acceptors (8, 13, 15). 
 
Clostripain.  The AArg inhibitors are the most potent with clostripain, as is expected 
from clostripain specificity.  Again, the potency of the AArg inhibitors with clostripain is 
lower than the ALys inhibitors with gingipain K.  For the AArg series, the disubstituted 
aromatic amides are the best P1’ substituent and the Michael acceptor warhead is more 
potent than the epoxide.   
 The ALys inhibitors are fair inhibitors of clostripain, but less potent than the 
AArg inhibitors.  Of the three enzymes, clostripain shows the least specificity between 
AArg and ALys P1 residues.   
 The AOrn inhibitors are only weak inhibitors of clostripain. 
 
Specificity.  A representative number of these inhibitors were tested with caspases -3, -6, 
-7, and -8, and all showed no inhibition.  The inhibitors tested were 2, 4, 8, 11, 15, 20, 23, 
and 24.  Therefore, these inhibitors are specific to the gingipains and clostripain over 
other clan CD proteases.  The caspases are potently inhibited by aza-peptide epoxides and 
Michael acceptors with a P1 AAsp, so this demonstrates that the P1 position is a major 







In aza-peptide epoxides and Michael acceptors we have found an extremely 
potent class of inhibitors for the gingipains and clostripain.  Of the three enzymes, 
gingipain K is the most susceptible to inhibition by this class of compounds.  This class 
of compounds is also highly specific, both between the three proteases investigated and 
over other clan CD enzymes.  Comparing Michael acceptor inhibitors with epoxide 
inhibitors containing the same P1’ moiety has led to the insight that the Michael 
acceptors with larger P1’ groups could be better inhibitors than comparable epoxides 
because of the two possible faces of attack.  We found that the inhibitor potency is 
tunable depending on the P1’ substituent present in the inhibitor.  Given their potency 
and specificity, these inhibitors could be useful tools in the research and treatment of the 





Enzyme Assays.  Gingipains R and K were assayed with the inhibitors using the 
incubation method, while clostripain was assayed using the progress curve method.  All 
enzyme activities were determined using the appropriate fluorogenic peptide 7-amino-4-
methylcoumarin substrates (AMC, excitation λ = 360 nm, emission λ = 405 nm).  The 
fluorescence was detected with a Tecan Spectraflour Microplate Reader (Tecan US, 
Research Triangle Park, NC).   
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Gingipain R.  Gingipain R was obtained from the lab of Jan Potempa (University 
of Georgia, Athens, GA) and is stored in a buffer of 20 mM Bis-Tris, 150 mM NaCl, 5 
mM CaCl2, 0.02% NaN3, pH 7.5, at a concentration of 1 mg/mL.  The kinetic assay 
buffer is 0.2 M Tris/HCl, 0.1 M NaCl, 5 mM CaCl2, 2 mM DTT, pH 7.5.  The enzyme 
was activated in the kinetic assay buffer for 1 hr at 0 oC prior to use.  Inhibitor in DMSO 
(25 µL) was diluted with the kinetic assay buffer (244 µL), and the inhibition reaction 
was initiated with the addition of enzyme (1 µL) at t = 0 s ([E] = 74.07 nM, [I] = 46.3 nM 
to 0.46 mM).  Aliquots (25 µL) of this incubation solution were removed at intervals and 
diluted into a solution containing kinetic assay buffer (100 µL), and the substrate Z-Phe-
Arg-AMC (26.7 µM) in DMSO (5 µL).  Enzyme activity was monitored by following the 
change in fluorescence at 465 nm.  Inhibition rates were determined in duplicate, and the 
error ranges were calculated. 
Gingipain K.  Gingipain K was obtained from the lab of Jan Potempa (University 
of Georgia, Athens, GA) and is stored in a buffer of 20 mM Bis-Tris, 150 mM NaCl, 5 
mM CaCl2, 0.02% NaN3, pH 8.0 at a concentration of 3 µM.  The kinetic assay buffer is 
0.2 M Tris/HCl, 0.1 M NaCl, 5 mM CaCl2, 2 mM DTT, pH 8.0.  The enzyme was 
activated in the kinetic assay buffer for 1 hr at 0 oC prior to use.  Inhibitor in DMSO was 
diluted with kinetic assay buffer, and the inhibition reaction was initiated with the 
addition of enzyme at t = 0 s ([E] = 5.43 nM).  Aliquots of this incubation solution were 
taken and diluted into a solution containing kinetic assay buffer, and the substrate Suc-
Ala-Phe-Lys-AMC·TFA (35 µM) with a small amount of DMSO to dissolve.  Enzyme 
activity was monitored by following the change in fluorescence at 465 nm. 
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Clostripain.  Clostripain was purchased from Worthington Biochemicals (Athens, 
GA) as a solid.  The enzyme was activated in the kinetic assay buffer 20 mM Tris/HCl, 
10 mM CaCl2, 0.005% Brij, 2 mM DTT, pH 7.6 for 1 hr at 0 oC.  The reaction was 
initiated by the addition of enzyme (25 nM final concentration) to a solution of kinetic 
assay buffer, inhibitor, and the substrate Z-Phe-Arg-AMC (0.273 mM, KM = 91.6 µM) 
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